

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Service Readiness and Limiting Factors to Manage Non-Communicable Diseases in Malawi: an Analysis of the 2019 Harmonized Health Facility Assessment Survey

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-072511
Article Type:	Original research
Date Submitted by the Author:	16-Feb-2023
Complete List of Authors:	Wang, Zicheng; Harvard University, T.H. Chan School of Public Health Cao, Yanjia; The University of Hong Kong, Department of Geography Ahmed, Sali; University of Washington, Department of Global Health Coates, Matthew M.; Brigham and Women's Hospital, Department of Medicine Twea, Pakwanja; University of Bergen, Department of Global Health and Primary Care (IGS); Ministry of Health, Department of Planning and Policy Development Ma, Mingyang; Harvard University, Department of Biostatistics Chiwanda Banda, Jonathan; Ministry of Health, Curative and Medical Rehabilitation Services; Kamuzu University of Health Sciences, Department of Community and Environmental Health Wroe, Emily; Brigham and Women's Hospital, Department of Medicine Bai, Lan; Nanjing University of Traditional Chinese Medicine, Department of Public Administration Watkins, DA; University of Washington, Seattle, Department of Medicine; University of Washington Seattle Campus, Department of Global Health Su, Yanfang; University of Washington, School of Medicine
Keywords:	Health Services Accessibility, Health Equity, Primary Health Care

SCHOLARONE™ Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Service Readiness and Limiting Factors to Manage Non-Communicable Diseases in Malawi: an Analysis of the 2019 Harmonized Health Facility Assessment Survey

Zicheng Wang¹, Yanjia Cao², Sali Amend ³, Matthew M. Coates⁴, Pakwanja Twea^{5,6}, Mingyang Ma⁷, Jonathan Chiwanda⁸, Emily B. Wroe⁴, Lan Bai⁹, David A. Watkins^{3,10}, Yanfang Su³*

- [1] Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115
- [2] Department of Geography, The University of Hong Kong, Hong Kong SAR
- [3] Department of Global Health, School of Public Health, University of Washington, WA, USA, 98195
- [4] Center for Integration Science in Global Health Equity, Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA, 02115
- [5] Bergen Centre for Ethics and Priority Setting, University of Bergen, Bergen, Norway
- [6] Department of Planning and Policy Development, Ministry of Health, Lilongwe, Malawi
- [7] Department of Biostatistics, Harvard University, Boston, Massachusetts, USA, 02115
- [8] Department of Clinical Services, Ministry of Health, Lilongwe, Malawi
- [9] Department of Public Administration, School of Health Economics and Management, Nanjing University of Traditional Chinese Medicine, Nanjing, China
- [10] Division of General Internal Medicine, Department of Medicine, University of Washington, 98195

^Co-first authors

*Corresponding author

Zicheng Wang

zicheng wang@hsph.harvard.edu

Yanjia Cao

yanjiac@hku.hk

Sali Amend

salia@uw.edu

Matthew M. Coates

mmcoates@bwh.harvard.edu

Pakwanja Twea

pakwanja.twea@health.gov.mw

Mingyang Ma

mma@hsph.harvard.edu

Jonathan Chiwanda

jonchiwanda@gmail.com

Emily Wroe

ewroe@pih.org

Lan Bai

dreamhour@163.com

David A. Watkins

davidaw@uw.edu

Yanfang Su

yfsu@uw.edu

ABSTRACT

Objectives: The burden of non-communicable diseases (NCDs) continues to grow in low-and-middle-income countries (LMICs), including Malawi. To inform policymakers and planners on the preparedness of the Malawian healthcare system and areas with limited services, we estimated the readiness of NCD services in the Malawian publicly financed healthcare facilities.

Method: We analyzed data from 564 publicly financed facilities in Malawi from the Harmonized Health Facility Assessment (HHFA) census survey, including 512 Primary Healthcare (PHC) and 52 Secondary and Tertiary health facilities. To characterize service readiness, we estimated the percentage of facilities where the necessary components required to provide NCD services are "available" and the percentage of facilities where the necessary components to provide NCD services are "functional" in a manner that allows service provision. Further, we estimated permanently unavailable items to identify service readiness bottlenecks.

Results: Less than 40% of the PHCs were ready to deliver service for any of the 13 NCDs included in the analysis. Only 5% of the PHC facilities were ready to provide chronic type 1 diabetes services, and only 7% and 8% were ready to provide services for chronic Rheumatic Heart Disease (RHD) and chronic Asthma. Around 38% of the Secondary and Tertiary facilities were ready to manage heart failure, and only 29% were ready to provide pain management services. Ensuring the availability of potential bottlenecks to service readiness like insulin and beclomethasone inhalers would improve the proportion of PHC facilities ready to provide type 1 diabetes and chronic asthma services from 5% to 43% and 8% to 71%, respectively.

Conclusion: We estimate that public health facilities in Malawi, especially at the PHC level, remain to experience gaps in essential medicines and equipment required for NCDs diagnosis and management. Targeted investments can support the health system in Malawi to make substantial improvements in NCDS services readiness.

Strengths and limitations of this study

- The HHFA survey does not include questions about the availability of the peak flow meter and micro nebulizer, which are essential for treating acute asthma.
- Data from the 2015 SPA survey about the availability of these two items suggest that we may have overestimated the service readiness for acute asthma.
- We haven't conducted any imputation for missingness.
- The HHFA survey did not collect data regarding the majority of medical components required for inpatient management apart from surgical services.
- The study is limited by the HHFA survey methodology, as the survey only covered a subset of medicines and equipment in surveying permanent unavailability.

OBJECTIVES

The growing burden of NCDs in low- and middle-income countries (LMICs) is particularly concerning. According to World Health Organization (WHO), 77% of the annual global NCD deaths occur in LMICs.(1) In 2021, NCDs caused 41 million deaths worldwide, among which

29 million died of the four major conditions, including cardiovascular disease, cancer, chronic respiratory disease, and diabetes. Several studies have reported low levels of NCD service readiness in LMICs.(2,3)

Located in sub-Saharan Africa with an 18.6 million population, Malawi remains one of the world's poorest countries, with a national Gross Domestic Product (GDP) of only \$640 per capita in 2021.(4) As a low-income country, Malawi suffers from the high burden of NCDs and their economic consequences that affect overall economic development and lead to catastrophic health expenditures (CHE) for Malawians seeking care.(5–7) As of 2019, NCDs accounted for 40% of Malawi's mortality, which increased from 30% in 2010.(8) A household survey conducted in 2012 in three rural districts in Malawi estimated that 21.3 % of all households with at least one member seeking care for an NCD condition incurred CHE due to NCDs.(7) Therefore, characterizing the readiness of health systems to manage NCDs in Malawi will enable the identification of areas that require investment to alleviate the existing and growing burden of NCDs.

Several prior studies have provisionally assessed the preparedness of the Malawian healthcare system. A 2018 study collected data from the 2013-2015 Malawi Service Provision Assessment (SPA) surveys and computed readiness scores to indicate the availability of medications, equipment, staff, and protocols in health facilities.(3) The study found that among diabetes, CVD, and chronic respiratory disease, diagnosing and treating diabetes have the lowest readiness.(3) Another SPA-based study on first-referral level hospitals in eight low-income countries, including Malawi, estimated the percentages of facilities with complete minimal sets of medications and equipment needed for thirteen conditions, including chronic asthma, acute asthma, chronic type 1 diabetes, chronic type 2 diabetes, acute diabetic events, hypertension (HTN), heart failure, and rheumatic heart disease (RHD), acute epilepsy, pain care, and minor surgery. (9) The study found that acute epilepsy services were the most available (95%), and acute asthma services were unavailable at any first-referral level hospitals in Malawi. However, findings from these studies only presented assessments around 2015, when the SPA dataset was published.(3,9) A report using more recent health facility data is necessary to present a current picture to inform policy and planning purposes. A more recent study estimated screening, diagnosis, management, and rehabilitation services readiness for NCDs based on a survey of 22 health facilities between November 2019 and March 2020.(10) The study found that cardiology and renal care were only available at two of the four surveyed tertiary hospitals and none of the district hospitals or health centers.(10) The two district hospitals surveyed had clinics where services for diabetes and hypertension were available. (10) At health centers, ten of 16 offered hypertension services, six offered diabetes care, and two offered asthma or COPD care. (10) In addition, only seven of the overall 22 facilities had half the essential drugs to treat NCDs.(10)Many facilities also lacked laboratory testing used in diagnosing and managing NCDs.(10)

Our study aims to fill the knowledge gap about the service readiness of the Malawian healthcare system for major NCD conditions using the most recent 2019 Harmonized Health Facility Assessment (HHFA) survey data that covered all publicly financed health facilities in the country. Our study has two main goals. The first goal is to estimate the service readiness of Malawian healthcare facilities by analyzing the availability and functionality of essential medications and equipment to diagnose and treat common NCD conditions that present early

in life and are associated with a significant disease burden. The conditions included in the analysis are acute and chronic asthma, hypertension (HTN), stage 1 and 2 and complicated HTN, heart failure, rheumatic heart disease (RHD), type 1 and 2 diabetes militias (DM), epilepsy, injuries, and minor surgical conditions, and chronic pain (Appendix Table 1). Because primary care facilities and secondary/tertiary hospitals are designed to provide different levels of care, we summarized the major NCD services at each level. The second aim is to identify potential bottleneck items that limit the facilities' service readiness.

METHODS

Sample and Representativeness

The healthcare delivery system in Malawi is divided into three ownership categories: public, private for-profit (PFP), and private not-for-profit (PNFP).(11) While PFP and PNFP facilities are slowly growing fee-charging systems, the publicly financed sector is free for everyone.(12) PFP and PNFP facilities are not open to everyone and only represent 11% of the facilities in the Malawian health system.(13) We focused on the free publicly financed facilities owned by the Malawian government or the Christian Health Associations of Malawi (CHAM) because of their accessibility to the population and because they comprise the large majority of the health system.(14) The Malawi health system consists of three levels: primary, secondary, and tertiary. Health centers and community hospitals are on the primary care level and offer ambulatory and maternity services. Secondary facilities are first-referral level hospitals (also called district hospitals), and the central hospitals are on the tertiary level.(11)

With a catchment area of 11 to 40 primary health centers, district hospitals serve a range of populations between 140,000 and 1,400,000.(15) District and central hospitals in Malawi are designed to provide Secondary and Tertiary Care. In contrast, health centers and rural/community hospitals are widely accessible to residents within local communities and thus recognized as Primary Healthcare (PHC) facilities.

The 2019 HHFA is a cross-sectional survey funded and developed by the World Health Organization, the World Bank, and other collaborators. It is an update of the Service Availability and Readiness Assessment (SARA) survey, built upon the SPA survey. The HHFA has a census sample of all facilities in Malawi. In this study, we acquired data from the 2019 HHFA, which surveyed 1,098 Malawian health facilities across all levels and ownerships. Our study sample included 576 public facilities in total: 515 PHCs (471 health centers and 41 rural/community hospitals) and 52 Secondary and Tertiary facilities (48 district hospitals and 4 central hospitals). The spatial distribution of all facilities is displayed in Appendix Figure 1. The 48 district hospitals included actual district hospitals, large health centres functioning as first-level-referral hospitals in certain districts (quasi-district hospitals), and first-referral-level CHAM hospitals. We removed Zomba Mental Hospital from our sample because we are only interested in facilities that provide general care. PHCs were expected as the first contact of the healthcare system for patients in Malawi. Patients in PHC facilities will be referred to the Secondary and Tertiary facilities for comprehensive diagnostics or more sophisticated care.

The total number of facilities in each category is summarized in Table 1. As a census survey database, the HHFA collected data from all functional facilities at the time of the survey. There were 485 health centres registered by the Administration of Health and only 471 surveyed by the HHFA. Therefore, the 14 health centres not surveyed in HHFA were defined as "nonfunctional." Our sample captures all publicly financed facilities; thus, the estimates represent the readiness of the publicly funded Malawian healthcare system.

Table 1. Summary of facility representation in each category

Primary Healthcare			Secondary and Tertiary facilities			
Facility type	Health centres	Rural/Community hospitals (RCH)	Total	District hospitals	Central hospitals	Total
HHFA samples	471**	41	512	48	4	52
Non- functional facilities*	14	0	14	0	0	0
Total	485	41	526	48	4	52

^{*}We consider the facilities not surveyed by the HHFA as "non-functional" because HHFA is a census survey.

Data Analysis

This study focused on the service readiness to diagnose and treat thirteen NCD conditions, including five acute and seven chronic conditions (see Appendix Table 1 for the list of conditions). Service readiness is measured as the percentage of health facilities with all functional medications and equipment to diagnose and treat common NCD conditions. We applied the list of medications and equipment for each condition from Gupta et al. study with minor refinements.(9)

We consulted local partners in the Ministry of Health to determine the expected facility level for each of the thirteen services. (Appendix Table 1) In addition to identifying expected services by facility type, we also examine data missingness to refine whether the required medicines and equipment are expected by facility type. The corresponding data in the HHFA survey were extracted for analysis, and we detailed the conditions, items, indicators, and related facility types in Appendix Table 2. When certain services were not expected at health centers, we only estimated these services in rural/community hospitals at the PHC level.

Regarding missingness, the HHFA survey did not include questions on peak flow meters and micro-nebulizers, which are the required equipment for asthma management. Therefore, we examined SPA data to understand how these missing variables might have affected the asthma readiness measure. For the variables with close to 100% missing data, we assumed that the item was not expected at the facility level.

Patient and Public Involvement:

No patient involved.

Measures

A medicine or equipment can be "available and functional," "available but not functional," "not available (at this time)," or "never available" at the facility. For each item, we calculated three

^{**}Three quasi-district hospitals were categorized as "District Hospitals": Ndirande Health Centre, Matawale Health Centre, and Mzuzu Health Centre.

indicators: 1) availability, 2) functionality, and 3) permanent unavailability.

Availability refers to the physical presence of the medicines or equipment required to provide services at the health facility during the survey. For example, a stethoscope is necessary for blood pressure measurement, and we measure the percentage of health facilities with a stethoscope.

$$Availability = \frac{\sum \text{\# of facilities with available element}}{\textit{Total number of facilities}}$$

Functionality refers to the presence of the medicines or equipment required to provide the service in operating conditions that allow service provision at the time of the survey. For example, the surveyor checked whether a stethoscope was working and whether insulin for type 1 diabetes was not expired and stored at the required temperature. We measure the percentage of facilities with available and working elements.

$$Functionality = \frac{\sum \# \ of \ facilities \ with \ available \ and \ working \ element}{Total \ \# \ of \ facilities}$$

Permanent unavailability is when the medicines or equipment is never present at the health facility. For example, insulin for type 1 diabetes was not present in the pharmacy for patients to dispense the prescription, and it was not a temporary situation.

$$Permanently\ unavilable\ sercice = \frac{\sum \#\ of\ facilities\ with\ elements\ that\ were\ never\ present}{Total\ \#\ of\ facilities}$$

For each facility, we estimated service readiness based on the functionality of all required items. We estimated service readiness bottlenecks based on permanent unavailability. The computation process is expressed as follows:

$$Servise\ Readiness = \frac{\sum f_i}{N},\ i \in [1,N],$$

$$f_i = \begin{cases} 1, & \text{if } item_1 = item_2 = item_j = item_m = 1, \ j \in [1,m] \\ 0, & \text{if } min(item_j) = 0. \end{cases}$$

According to the law of the minimum, service readiness is dictated by the limiting factor, a principle developed in agricultural science by Carl Sprengel (1840).(9) The limiting factor that prevents the service from being ready was identified in our analysis.

Supply Bottleneck =
$$\frac{\sum pu_i}{N}$$
, $i \in [1,N]$

Where f_i refers to functionality at facility i, and pu_i refers to permanent unavailability at facility i. When a facility has all essential components available and functioning, it is labeled "ready." Otherwise, the facility is labeled as "Not ready." We estimated service readiness by NCD condition.

RESULTS

Overall service readiness by condition and item functionality are presented in Figure 1. Certain

items contributed substantially to low service readiness scores for conditions. For example, beclomethasone inhalers, salbutamol inhalers, and stethoscopes were needed to manage chronic asthma. Although 71% and 92% of PHC were equipped with functional salbutamol inhalers and stethoscopes, the service readiness was 8% because only 8% of PHC were equipped with beclomethasone inhalers. Beclomethasone inhaler was a limiting item for chronic asthma service readiness among PHCs. Other limiting items among PHCs include calcium channel blockers for hypertension services, insulin for type 1 diabetes, ultrasound equipment for heart failure, injectable epinephrine in case of an allergic reaction to injectable benzathine penicillin for chronic RHD, and functional x-ray machines for acute asthma. Among the Secondary and Tertiary facilities, increasing the number of functional beclomethasone inhalers would also improve their readiness for chronic asthma service.

Regarding missingness and potential bias, nebulizer and peak-flow meter measures were not included in the HHFA survey, and we analyzed 2015 SPA data to understand potential bias in our estimates. It turns out that nebulizers were available at three of four central hospitals but only at 22% of rural/community hospitals. Peak-flow meters were available at one of four central hospitals but only at 5% of rural/community hospitals. Our estimates based on 2019 HHFA data are likely to overestimate asthma service readiness. Service readiness for acute asthma was estimated to be 15%-17% at the PHC level and 44%-50% at secondary and tertiary hospitals based on HHFA surveys. However, the service availability among first-level referral hospitals was estimated to be 0 based on 2015 SPA data, in which the peak flow meter was the limiting factor at 5% availability. If the peak flow meter and nebulizer had been at the same level as the 2015 SPA survey results (Appendix Table 3), acute asthma service readiness would have been less than 5% at PHCs and less than 6% at secondary and tertiary hospitals. While availability may have grown since 2015, if availability remains unchanged, it may be an alarming limiting factor for the overall readiness for acute asthma care.

Given that SPA data were collected in 2015 and with a smaller sample size than HHFA, we did not incorporate 2015 SPA data into 2019 HHFA data. Instead, we used it to shed light on potential biases. This is an example to show that when the missing variable is the limiting factor, the missingness might significantly bias the estimation of service readiness. According to the guideline and missing data investigation, we assumed that the following services were not expected at health centers: heart failure, chronic RHD, acute asthma, acute diabetic events, acute epilepsy, and injuries. Except for the aforementioned missingness, all other variables have less than 25% missing data.

Figure 1: Service readiness and service functionality for each essential medical component at PHCs and Secondary and Tertiary facilities

To compare the service readiness of both PHC and Secondary and Tertiary facilities for chronic and acute NCD conditions, we visualized the readiness score in Figure 2. Overall, for all NCD conditions, the service readiness of Secondary and Tertiary facilities was higher than the PHCs in Malawi. We found that the service readiness was lower than 35% for all NCD conditions we studied in PHC facilities. The readiness to treat type 1 diabetes and chronic RHC was only 5% and 7%, respectively. In contrast, we found that Secondary and Tertiary facilities in Malawi were reaching full readiness for type 2 diabetes (94%), hypertension (88%), and acute epilepsy (85%). However, relatively lower readiness was also identified for chronic asthma, pain care, heart failure, chronic Rheumatic Heart Disease (RHD), moderate/severe acute asthma, and injuries/ acute minor surgical services.

Figure 2: NCD service readiness of the Malawi health system by level

In this research, we further analyzed the essential equipment and medications that are "permanently unavailable." As shown in Table 2, one of our "bottleneck" items, the beclomethasone inhaler, has been permanently unavailable in 74% of PHCs. In addition, 81% of the PHCs never have access to insulin. Table 2 also reveals items well in stock in the Malawi healthcare system. Oral pain medications, salbutamol inhalers, and diazepam injections were three examples with zero permanent unavailability in the HHFA survey.

Table 2: Permanent unavailability of essential equipment and medications among PHC and Secondary and Tertiary facilities.

	Condition	Essential Equipment & Medication	PHC (N = 512)	Secondary & Tertiary facilities (N = 52)
	Chronic Asthma	Beclomethasone inhaler	74%	29%
	(PHC)	Salbutamol inhaler	8%	0%
	Hypertension (PHC)	At least two or three of: calcium channel blocker, ACE inhibitor, thiazide, atenolol	12%	0%
Chronic Conditions	Type 1 diabetes (PHC)	Insulin	81%	2%
	Type 2 diabetes			
	(PHC)	Metformin or glibenclamide	48%	0%
		Oral pain medication	0%	0%
	Pain care	Injectable morphine or pethidine	7%	19%

		Atenolol or other beta-blocker	24%	6%
		Captopril, enalapril or other ACE inhibitor	20%	6%
	Heart failure	Furosemide	12%	2%
		Benzathine penicillin	44%	8%
	Chronic RHD	Injectable epinephrine	5%	10%
	Mild/moderat e acute	Prednisolone	10%	0%
	asthma			
	Prednisolone		10%	0%
	Moderate/sev ere acute	Salbutamol inhaler	0%	0%
	asthma	Hydrocortisone injection	32%	8%
Acute	Acute diabetic	Injectable glucose	0%	2%
Conditions	events	Insulin	49%	2%
	Acute epilepsy	Diazepam injection	0%	0%
	,	Lidocaine in minor surgical area	2%	0%
	injuries/ acute minor surgical	Skin disinfectant in minor surgical area	5%	2%
	conditions	Sutures in minor surgical area	5%	0%

DISCUSSION

In this research, we estimated service readiness for NCD treatment in Malawi based on the 2019 HHFA database. The analysis reveals that less than 40% of PHCs in Malawi are ready to deliver service for any of the 13 NCD services included in the analysis. PHC facilities' readiness to provide care for chronic conditions is low, with the highest readiness of 34% for managing Stage 1/2 hypertension, while only 5% of the PHC facilities were ready to manage type 1 diabetes. PHC facilities' service readiness for acute conditions management was highest for acute epilepsy, with 37% of the PHC facilities having diazepam injections, while only 15% of the PHC facilities were ready to manage moderate and severe asthma. Compared to PHC facilities, service readiness for the 13 NCD conditions included in the analysis is considerably higher in secondary and tertiary facilities. However, services for chronic conditions like pain care, heart failure, and chronic asthma have low readiness scores even at secondary and tertiary facilities (29%, 38%, and 40%, respectively). Our results lined up with other studies that Malawi's health system requires substantial improvement to prepare for the growing burden of NCDs in the country.(9,10,16)

It is globally recognized that PHC facilities are essential in providing services for NCDs and routine care for the elderly and are a cornerstone for achieving universal health coverage. In 2013 the WHO Package of Essential Non-communicable Disease Interventions (WHO PEN) included managing cardiovascular diseases, diabetes, chronic respiratory diseases, and cancer prevention and screening through primary care platforms as a minimum requirement for universal coverage reforms in low-resource settings.(17) The 2018 Declaration of Astana on PHC emphasizes the role of PHC facilities in providing comprehensive services, including the control and management of NCDs.(18) The World Bank recommends reinforcing PHC networks to provide universal coverage of services required for the prevention, early detection, and low-cost, high-quality management of chronic NCDs.(19) The essential health package (EHP) developed by the Ministry of the health of Malawi (MOH) included the management of diabetes type 1 and 2, hypertension, and treatment of injuries as interventions to be provided as free services at the point of care at primary and secondary levels.(20) However, our study shows that most PHC facilities had low service readiness for common chronic conditions, while required medicines and equipment for chronic condition management were more ready at secondary and tertiary levels. Our analysis indicates suboptimal functionality of essential services that are part of the EHP. This is in line with MOH concerns about the suboptimal implementation of the EHP policy due to inadequate resources, low awareness among stakeholders, and insufficient operationalization of the policy due to the lack of clear financial mechanisms to ensure the provision of free-of-charge services at the point of care. (20)

Ensuring the availability of limiting items would improve the proportion of PHCs ready to provide care for type 1 diabetes from 6% to 43%. Similarly, increasing the availability of beclomethasone inhalers would enhance the service readiness for chronic asthma from 8% to 71% among PHCs and from 50% to 88% among Secondary and Tertiary facilities. Asthma management is not part of the NCD intervention package included in the EHP of Malawi, and the Standard Treatment Guidelines for Malawi state that beclomethasone is only expected to be provided at the tertiary level.(20,21) However, the WHO considers beclomethasone as an essential and cost-effective intervention that can be provided through PHC platforms.(22,23) Service readiness for NCD treatment in Malawi can be significantly improved by ensuring the availability and functionality of these items. Increasing the availability of limiting items is in line with the WHO calls to increase coverage and close the gap between the available and needed high-impact essential NCD interventions to reduce the burden, healthcare costs, and suffering due to major NCDs in LMICs.(17,24) This study sheds light on the compatibility of regulatory guidelines and recommends updating the 2015 Standard Treatment Guidelines for Malawi in line with changing priorities and policies.

This study has the merit of a census sample for analysis and specified facility types. An assessment of service readiness for NCDs in five countries, including Malawi, reported a total NCD service capacity score of 59 out of 100 in their study, indicating a low readiness compared to the benchmark (3), leaving condition-specific readiness unknown. In addition, some prior research only analyzed the service readiness for first-level-referral hospitals and all facilities in Malawi, missing detailed information about each service level.(3,9) In our study, we divided facilities by PHCs and Secondary and Tertiary facilities and categorized facilities into health centers, rural/community hospitals, district hospitals, and central hospitals. The census samples from HHFA provide the opportunity to estimate NCD service readiness at the primary, secondary, and tertiary levels. Banda and colleagues assessed capacity across a range of facility types; however, the sample consisted of only 22 facilities out of over 550 in the country(3,9,10).

Overall service readiness scores depended partly on the total number of items comprising the score. When the number of required equipment and medications increased, the likelihood of

service readiness decreased. For example, seven essential medications are required for heart failure treatment, and the overall readiness score is only 38% because only a small number of facilities have all seven components ready. In contrast, for acute epilepsy, which only required diazepam injection, the service readiness was 85%.

There are several limitations of this study. First, the HHFA survey does not include questions about the availability of the peak flow meter and micro nebulizer, which are essential for treating acute asthma. Data from the 2015 SPA survey about the availability of these two items suggest that we may have overestimated the service readiness for acute asthma. Second, we haven't conducted any imputation for missingness; future research is warranted in dealing with missing data through imputation. Third, apart from basic surgical care, the HHFA survey did not collect data regarding the majority of medical components required for inpatient management. Fourth, our study is limited by the HHFA survey methodology, as the survey only covered a subset of medicines and equipment in surveying permanent unavailability. Hence understanding of permanently unavailable items does not represent the full set of items required for NCDs management. In addition, the study by Banda et al.(10) of a smaller number of health facilities assessed other dimensions not included in the HHFA survey, such as whether facilities kept reliable records for NCD patients, and also supplemented the data with qualitative interviews that deepened the understanding of constraints. Last but not least, future studies should also investigate the Malawi health system's preparedness for emergency and critical care, which we did not include in this study.

Our findings have several implications for improving the service readiness of NCDs in Malawi. First, there is a gap between the readiness of PHCs and Secondary and Tertiary facilities. Our study suggests that PHCs require high-priority investments to improve NCD service availability. While health centres and rural/community hospitals may not be expected to perform complete diagnostics or treatment for complicated conditions, these primary care facilities are well-positioned to provide a comprehensive set of basic NCD services, given their accessibility. Second, targeting items on our list of limiting factors and permanently unavailable times presents an opportunity to update regulatory guidelines and achieve the most significant increases in service readiness for particular conditions. The efficient investment in NCD treatment potentially speeds up the medical service optimization in Malawi.

Figures Legend:

Figure 1: Service readiness and service functionality for each essential medical component at PHCs and Secondary and Tertiary facilities	The figure presents service readiness for 13 NCD conditions and illustrates the components contributing to the service readiness score calculation comparing PCH
	and higher-level health facilities.
Figure 2: NCD service readiness of the Malawi health system by level	The figure presents the service readiness of 13 NCD conditions in the health facilities in
William Housen System by Tever	Malawi. Figure 2 compares acute and chronic NCD service availability across the health service levels.

a. Contributorship statement

Contributors ZW, YC, and SA led the literature review and wrote the first draft of the manuscript. PT and JC provided data and supporting documents. ZW and LB analyzed the data, and MM replicated the estimates. ZW and MM produced the tables. YC and SA had the figures. MC, PT, EW, and DW contributed to conceiving the study, refining the methods, and interpreting the results. DW acquired funding for the research. YS led the study design, method development, and result interpretation. All the authors have made significant intellectual or practical contributions, critically revised the manuscript, and approved the final version of this paper.

b. Competing interests

We declare that non of the authors and coauthors have any financial or non-financial competing interests that may influence the analysis or the interpretation of this paper.

c. Funding

This work was supported by the Bergen Centre for Ethics and Priority Setting (BCEPS) with support from the Trond Mohn Foundation and the Norwegian Agency for Development Cooperation (NORAD), project number 874 789 542.

d. Data sharing statement

The data supporting this study's findings were obtained through the FMOH Malawi and are not available in a public, open-access repository.

e. Ethics approval statement Not a human subject research. Ethical approval exempt

Acknowledgments: The authors thank the Ministry of Health in Malawi. They are also grateful for all the valuable comments from editors and reviewers.

References

- 1. World Health Organization. Noncommunicable disease [Internet]. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
- 2. Leslie HH, Spiegelman D, Zhou X, Kruk ME. Service readiness of health facilities in Bangladesh, Haiti, Kenya, Malawi, Namibia, Nepal, Rwanda, Senegal, Uganda and the United Republic of Tanzania. Bull World Health Organ. 2017 Nov 1;95(11):738–48.
- 3. Moucheraud C. Service Readiness For Noncommunicable Diseases Was Low In Five Countries In 2013–15. Health Aff (Millwood). 2018;37(8).
- 4. The World Bank. The World Bank Data Malawi [Internet]. 2022. Available from: https://data.worldbank.org/country/MW
- 5. Kim ET, Singh K, Speizer IS, Angeles G, Weiss W. Availability of health facilities and utilization of maternal and newborn postnatal care in rural Malawi. BMC Pregnancy Childbirth. 2019 Dec 17;19(1):503.
- 6. Macarayan EK, Gage AD, Doubova SV, Guanais F, Lemango ET, Ndiaye Y, et al. Assessment of quality of primary care with facility surveys: a descriptive analysis in ten

- low-income and middle-income countries. Lancet Glob Health. 2018 Nov 1;6(11):e1176–85.
- 7. Wang Q, Brenner S, Kalmus O, Banda HT, De Allegri M. The economic burden of chronic non-communicable diseases in rural Malawi: an observational study. BMC Health Serv Res. 2016 Sep 1;16(1):457.
- 8. Wroe EB, Kalanga N, Dunbar EL, Nazimera L, Price NF, Shah A, et al. Expanding access to non-communicable disease care in rural Malawi: outcomes from a retrospective cohort in an integrated NCD–HIV model. BMJ Open. 2020 Oct;10(10):e036836.
- 9. Gupta N, Coates MM, Bekele A, Dupuy R, Fénelon DL, Gage AD, et al. Availability of equipment and medications for non-communicable diseases and injuries at public first-referral level hospitals: a cross-sectional analysis of service provision assessments in eight low-income countries. BMJ Open. 2020 Oct;10(10):e038842.
- 10. Banda CK, Hosseinipour MC, Kumwenda J, Banda NPK, Lutala P, Makwero M, et al. Systems Capacity To Conduct Non-Communicable Disease Focused Implementation Research In The Malawian Health Sector: A National Needs Assessment [Internet]. In Review; 2021 May [cited 2021 Nov 23]. Available from: https://www.researchsquare.com/article/rs-496152/v1
- 11. MOH, Malawi. Health Care System [Internet]. 2016 [cited 2022 Dec 12]. Available from: https://www.health.gov.mw/index.php/2016-01-06-19-58-23/national-aids
- 12. Makwero MT. Delivery of primary health care in Malawi. Afr J Prim Health Care Fam Med. 2018;10(1):e1–3.
- 13. World Health Organization. Malawi: Country Cooperation Startegy at a glance [Internet]. 2018. Available from: http://apps.who.int/iris/bitstream/handle/10665/136935/ccsbrief_mwi_en.pdf;jsessionid= 6622A9B77AC48437784A63B1C127472E?sequence=1
- 14. Zeng W, Sun D, Mphwanthe H, Huan T, Nam JE, Saint-Firmin P, et al. The impact and cost-effectiveness of user fee exemption by contracting out essential health package services in Malawi. BMJ Glob Health. 2019 Apr;4(2):e001286.
- 15. Government of Malawi. Malawi Millennium Development Goal Endline Report [Internet]. UNDP; 2015. Available from: http://www.mw.undp.org/content/dam/malawi/docs/general/UNDP_MW_EDP_MDG_bo ok final.pdf
- 16. Shiroya V, Shawa N, Matanje B, Haloka J, Safary E, Nkhweliwa C, et al. Reorienting Primary Health Care Services for Non-Communicable Diseases: A Comparative Preparedness Assessment of Two Healthcare Networks in Malawi and Zambia. Int J Environ Res Public Health. 2021 May 10;18(9):5044.
- 17. World Health Organization. Implementation tools: Package of Essential Noncommunicable (PEN) disease interventions for primary health care in low-resource settings [Internet]. Копенгаген: World Health Organization; 2013 [cited 2022 Oct 18]. (Сети фактических данных по вопросам здоровья; Сводный доклад №71). Available from: https://apps.who.int/iris/handle/10665/341421

- 18. World Health Organization. Declaration of Astana [Internet]. 2018 [cited 2022 Oct 18]. Available from: https://www.who.int/docs/default-source/primary-health/declaration/gcphc-declaration.pdf
- 19. The World Bank. Walking the Talk: Reimagining Primary Health Care After Covid-19. 2022 p. 225.
- 20. MOH, Malawi. The Essential Health Package (EHP) [Internet]. Ministry of the health Republic of Malawi. 2016 [cited 2022 Oct 25]. Available from: https://www.health.gov.mw/index.php/essential-health-package
- 21. MOH, Malawi. Malawi Standard Treatment Guidelines Essential Medicines List 2015.pdf [Internet]. 2015 [cited 2022 Dec 12]. Available from: https://extranet.who.int/ncdccs/Data/MWI_D1_Malawi-Standard-Treatment-Guidelines-Essential-Medicines-List-2015.pdf
- 22. World Health Organization. 2008-2013 action plan for the global strategy for the prevention and control of noncommunicable diseases: prevent and control cardiovascular diseases, cancers, chronic respiratory diseases and diabetes. Plan Action 2008-2013 Pour Strat Mond Lutte Contre Mal Non Transm. 2009;42.
- 23. World Health Organization. Prevention and control of noncommunicable diseases: guidelines for primary health care in low resource settings [Internet]. Geneva: World Health Organization; 2012 [cited 2022 Dec 12]. 68 p. Available from: https://apps.who.int/iris/handle/10665/76173
- 24. World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. 2013.





Figure 1: Service readiness and service functionality for each essential medical component at PHCs and Secondary and Tertiary facilities

1243x1035mm (130 x 130 DPI)



Acute Asthma (moderate/ severe)

| D. Acute Conditions | 85% | 65% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37% | 37%

Figure 2: NCD service readiness of the Malawi health system by level 512x390mm (130 x 130 DPI)

Appendix Table 1: Service expected at each level

Condition	Primar	y Health Care	-	and Tertiary ities
	Health	Rural/Community	District	Central
	Centers	Hospitals	Hospitals	Hospitals
Chronic conditions				
Chronic asthma	X	x	X	х
Hypertension (stage 1 or				
2)	X	X	X	х
Type 1 diabetes	X	x	X	х
Type 2 diabetes	X	x	X	х
Oral pain care	X	x	X	х
Injectable pain care	4	x	X	X
Hypertension requiring				
three or more				
antihypertensive classes	Х	X	X	х
Heart failure		х	X	х
Chronic RHD		х	X	х
Acute conditions				
Mild/moderate acute				
Asthma		X	Х	x
Moderate/severe acute				
Asthma		x	х	х
Acute diabetes		х	х	х
Acute epilepsy		х	x	х
injuries/ acute minor				
Surgical conditions+		х	х	Х

Appendix Table 2: Service Indicators

Conditions		Availabilit	1		Facility Types
Conditions	equipment and			Available"	' '
		ľ.	*	Data	Burveyeu
	inculcations	indicators	marcators	Data Availabilit	
Mild/moderat	Functional X-	T125 01	T125 01	y No Data	1,2,3
					1,2,3
	•	(Y = 1,2,3;	,		
Asthma		N = 4,NA		N - D - 4 -	1 2 2 4
	' -	HH101_2		No Data	1,2,3,4
		2 (Y =	`		
	V-	"Yes", N =			
		"No",	, ,		
		NA) OR			
		HH1012			
		3 (cylinder)	`		
			"Yes", N =		
		"Yes", N =	"No", NA)		
		"No", NA)			
		No Data	No Data	No Data	No Data
		(used SPA			
	0	data for			
	outpatient	estimation)			
	area				
		U103_10		_	1,2,3,4
		(Y = 1, 2;	(Y = 1; N =	== 5	
		N =	2,3,4,5,NA		
		3,4,5,NA))		
	Pulse	HH1018	HH101A8	No Data	1,2,3,4
	oximeter	(Y =	`		
		"Yes", N =	"Yes", N =		
		"No", NA)	"No", NA)		
	Salbutamol	U103_21	U103_21	U103_21	1,2,3,4
	inhaler	(Y = 1,2; N)	(Y = 1; N =	== 5	
		=	2,3,4,5,NA		
		3,4,5,NA))		
Moderate/sev	Functional X-	T125_01	T125_01	No data	1,2,3
ere acute	ray machine	(Y = 1,2,3;	(Y = 1; N =		
Asthma		N = 4,NA	2,4,NA)		
	Oxygen	HH1012	HH101A22	No data	1,2,3,4
	"	2 (Y =			. , ,
	_	"Yes", N =	1`		
<u> </u>	J	, 1 .	, 1 .	<u> </u>	

	(cylinder or	"No",	"No", NA)		
	1 . •	NA) OR	OR		
		HH1012	HH101A23		
		3 (cylinder)	(Y =		
		(Y =	"Yes", N =		
		"Yes", N =	"No", NA)		
		"No", NA)	ĺ		
	Peak flow	No Data	No data	No data	No data
	meter in NCD	(used SPA			
	or general	data for			
	outpatient	estimation)			
	area				
	Prednisolone	U103_10	U103_10	U103_10	1,2,3,4
		(Y = 1, 2;	(Y = 1; N =	== 5	
		N =	2,3,4,5,NA		
		3,4,5,NA))		
	Pulse	HH1018	HH101A8	No data	1,2,3,4
	oximeter	(Y =	(Y =		
		"Yes", N =	"Yes", N =		
		"No", NA)	"No", NA)		
	Salbutamol	U103_21	U103_21	U103_21	1,2,3,4
	inhaler	(Y = 1,2; N)	(Y = 1; N =	== 5	
		=	2,3,4,5,NA		
		3,4,5,NA)			
	Micro	No Data	No Data	No Data	No Data
	nebulizer in	(used SPA			
	NCD or	data for			
	general	estimation)			
	outpatient				
	area				
	Hydrocortisone	U103_11	U103_11	U103_11	1,2,3,4
	injection	(Y = 1,2; N		==5	
			2,3,4,5,NA		
		3,4,5,NA))		
Acute	Blood glucose	T105_01	No Data	No Data	1,2,3,4
diabetes		(Y = 1,2; N)			
		=3,NA)			
	Blood pressure			No Data	1,2,3,4
	* *	5 (Y =	`		
		"Yes, N =			
	Γ	"No",NA)	"No",NA)		
	outpatient				
	area				

	Infusion kit for	M116 161(No Data	No Data	1,2,3,4
	intravenous	Y = "Yes",			, , ,
	fluids	N = "No")			
	Injectable	U103_03	U103_03	U103_03	1,2,3,4
	glucose	(Y = 1,2; N)	(Y = 1; N =	== 5	
		=	2,3,4,5,NA		
		3,4,5,NA))		
	Insulin	U103_02	U103_02	U103_02	1,2,3,4
		(Y = 1,2; N	(Y = 1; N =	==5	
		=	2,3,4,5,NA		
		3,4,5,NA))		
	Liver and	T113_03	T123_01	T123_01	1,2,3
	kidney	(Y = 1,2; N	(Y = 1; N =	==5	
	function	=3,NA)	2,3,4,NA)		
	diagnostics	Or			
	(creatinine,	T122_01			
	electrolytes)	(Y = 1,2; N			
		=3,NA) Or			
		T123_01			
		(Y = 1,2,3;			
		N = 4,NA			
Acute	Diazepam				All facility types
epilepsy	injection	(Y = 1,2; N)			
			2,3,4,5,NA		M103.Yes.Contains
) Or	==5	(8)
			U126_05		
			(Y = 1; N = 1)		
		(Y = 1,2; N)	2,3,4,5,NA		
		= 2.45 N(A)	P		
Turing and a sector	T : 1 : : -	3,4,5,NA)	11105 10	III05 10	1 2 2 4
Injuries/ acute		$U125_{12}$			1,2,3,4
conditions+	minor surgical	1			
conditions+	area	=3,4,3,NA)	2,3,4,5,NA		
	Nasogastric	RR115 7	RR115A7	No Doto	1,2,3
	tubes in minor	_	(Y =	uno Dala	1,4,3
	surgical area	"Yes", N =	`		
	Surgical area	"No", NA)	-		
	Needle holder		RR115A3,(No Data	1,2,3
	in minor		Y = "Yes",	ı 10 Dala	1,4,5
	surgical area	"Yes", N =			
	3151041 4104	"No", NA)			
	1	1110 ,1111)	r 14 */	I	

	Oxygen	HH1012	HH101A22	No Data	1,2,3,4
	• •	2 (Y =			, , ,
		"Yes", N =	`		
	I . •	"No",			
		NA) OR			
		HH1012			
		3 (cylinder)			
		(Y =	,		
		`	"No", NA)		
		"No", NA)	ŕ		
	Retractor in	RR115_5	RR115A5	No Data	1,2,3
	minor surgical	(Y =	(Y =		
	area	"Yes", N =	"Yes", N =		
		"No",	"No",		
		NA))	NA))		
	Scalpel in	RR115_4	RR115A4	No Data	1,2,3
	minor surgical	(Y =	(Y =		
	area	"Yes", N =	"Yes", N =		
		"No",	"No",		
		NA))	NA))		
	Skin	U125_05	U125_05	U125_05	1,2,3,4
	disinfectant in	(Y = 1,2; N)	(Y = 1, N =	==5	
	minor surgical	=	2,3,4,5,NA		
	area	3,4,5,NA)			
	Surgical	RR115_6	RR115A6	No Data	1,2,3
	scissors in	(Y =	(Y =		
	minor surgical	"Yes", N =	"Yes", N =		
	area	"No", NA)	"No", NA)		
		U125_09			1,2,3,4
	minor surgical	(Y = 1,2; N)	(Y = 1; N =	==5	
	area	= 3,4,5)			
	Tourniquet in			No Data	1,2,3
	minor surgical	· ·	(Y =		
		"Yes", N =			
		"No", NA)	. ,		
	Availability of	Availabilit			Facility Types
	complete	ľ	-	Available"	Surveyed
		Indicators		Data	
	equipment and			Availabilit	
	medications			у	
('hronic	Beclomethason	_		U103_09	1,2,3,4
asthma	e inhaler	(Y = 1,2; N)		==5	
		= 3,4,5,NA			

			2 2 1 5 NI A		
			2,3,4,5,NA		
	Salbutamol	U103_21) 11103-21	II103 21	1,2,3,4
		(Y = 1,2; N)			1,2,5,7
	iiiiaici		2,3,4,5,NA		
		3,4,5,NA))		
		HH101_13	HH101A3	No Data	1,2,3,4
		(Y =			, , ,
		"Yes", N =	"Yes", N =		
		"No", NA)	"No", NA)		
	At least two of:	U103_04,	U103_04,	U103_04	1,2,3,4
	calcium	U103_05,	U103_05,	==5 AND	
	channel	U103_06,	U103_06,	U103_05	
	blocker, ACE				
		(Y = 1,2; N)			
		= 3,4,5)			
	atenolol	0		U103_07	
Hypertension				==5	
	Blood pressure			No data	1,2,3,4
	apparatus	5 (Y =			
		"Yes, N =	•		
		"No",NA)		NT 1	1 2 2 4
	-	HH101_13		No data	1,2,3,4
		(Y = "Yes", N =	`		
		"No", NA)			
		U103_04,		7	1 2 3 4
		U103_04, U103_05,			1,2,5,7
		U103_06,			
	blocker, ACE		· ·		
	inhibitor,thiazi				
		= 3,4,5)			
Hypertension		·		U103_07	
requiring				==5	
three or more	Blood pressure	HH1011	HH101A15	No data	1,2,3,4
antihypertensi ve classes	apparatus	5 (Y =	(Y =		
VC Classes		"Yes, N =	·		
		"No",NA)			
	Stethoscope	HH101_13		No data	1,2,3,4
		`	(Y =		
		"Yes", N =			
		"No", NA)	"No", NA)		

	Adult scale	HH101_1	HH101A1	No Data	1,2,3,4
		(Y =		110 2 414	1,2,3,1
		"Yes", N =	`		
		"No", NA)			
	Atenolol or	U103_06		IJ103_06	1 2 3 4
		(Y = 1,2; N)	_	<u> </u>	1,2,3,4
	blocker		2,3,4,5,NA		
	DIOCKCI	– 3,4,5,NA))		
		5,7,5,1111)	,		
	Blood pressure	HH1011	HH101A15	No data	1,2,3,4
	apparatus	5 (Y =	(Y =		
		"Yes, N =	"Yes", N =		
		"No",NA)	"No",NA)		
	Captopril,	U103_04	U103_04	U103_04	1,2,3,4
Heart failure	enalapril or	(Y = 1,2; N)	(Y = 1; N =	==5	
	other ACE	F	2,3,4,5,NA		
	inhibitor	3,4,5,NA))		
	Furosemide	U103_13	U103_13	U103_13	1,2,3,4
		(Y = 1,2; N)	(Y = 1; N =	==5	
			2,3,4,5,NA		
		3,4,5,NA))		
	Stethoscope	HH101_13	HH101A3	No data	1,2,3,4
	1	(Y =	(Y =		
		"Yes", N =			
		"No", NA)	"No", NA)		
		T125_02		No Data	1,2,3
		(Y = 1,2,3;			, ,
		N = 4,NA			
		U106_18		U106 18	1,2,3,4
		(Y = 1,2; N)			
		` ,	2,3,4,5,NA		
		3,4,5,NA))		
		, , , ,			
	Injectable	U125_20	U125 20	U125 20	1,2,3
		(Y = 1,2; N)			-,-,-
chronic RHD	1 F		2,3,4,5,NA		
		3,4,5,NA)		==5	
			U103_12		
		U103_12	_		
		(Y = 1,2; N)	,		
		= 1,2,11)		
		3,4,5,NA)			
	I	- , -,~ ,- , - ,	1	1	<u> </u>

	D. 1.1	T107 01			1 2 2 4
	Blood glucose			No data	1,2,3,4
	test	(Y = 1,2; N)			
	equipment	=3,NA)			
Type 1	Insulin	U103_02	U103_02	U103_02	1,2,3,4
diabetes		(Y = 1,2; N)	(Y = 1; N =	==5	
		=	2,3,4,5,NA		
		3,4,5,NA))		
	Blood glucose	T105_01	No data	No data	1,2,3,4
	test	(Y = 1,2; N)			
	equipment	=3,NA)			
		U103_01	U103_01	U103_01	1,2,3,4
	glibenclamide				
Type 2			2,3,4,5,NA		
diabetes		3,4,5,NA)		U103_14	
			U103 14		
		U103_14	(Y = 1; N =		
		(Y = 1,2; N)	*		
		3,4,5,NA)			
	Injectable	U127_07	U127 07	U127 07	1,2,3
	•	(Y = 1,2; N)			7 7-
	pethidine	=3,4,5,NA)			
	F		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
	Oral pain	U103 20	U103_20	U103_20	1.2.3.4
	medication	_	OR	==5 AND	1,2,5,1
Pain care	(paracetamol,			U103_17	
	ibuprofen,		OR	==5 AND	
	aspirin or		U111_08	U111_08	
	diclofenac)		OR	==5 AND	
	dicioicilac)		U103_08;		
			Y = 1; N =		
		1,∠, 1N	2,3,4,5,NA		
		- 2 1 5 NI A	2,3,4,3,INA		
		3,4,5,NA			

^{*} Facility types: 1 = central hospitals, 2 = district hospitals, 3 = rural/community hospitals, 4 = health centers

Appendix Table 3: nebulizer and peak-flow meter availability from SPA data, 2015

Medical	Facility type	Total	Facilities	%
component		facilities	with	availability
			availability	
Nebulizer	Central hospital	4	3	75.00
	District hospital	24	6	25.00
	Other hospital	47	28	59.25
	Rural / community	41	9	21.95
	hospital			
	Health center	473	24	5.07
	Clinic	317	38	12.02
	Health post	20	NA	NA
	Maternity	4	NA	NA
	Dispensary	47	1	2.00
	Total	977	109	11.09
Peak-flow	Central hospital	4	1	25.00
meter				
	District hospital	24	1	4.17
	Other hospital	47	13	27.58
	Rural / community	41	2	4.88
	hospital			
	Health center	473	8	1.68
	Clinic	317	12	3.79
	Health post	20	NA	0.00
	Maternity	4	NA	0.00
	Dispensary	47	NA	0.00
	Total	977	37	3.76

Appendix Table 4: Missingness in HHFA data

		Health Center (n=471)		Rural Community Hospital (n=41)		District Hospital (n=48)		Central Hospital (n=4)	
Condit ion	Essenti al Equip ment & Medica tion	Missin g data: Availa ble Compo nents	Missin g data: Functi onal Compo nents	Missin g data: Availab le Compo nents	Missin g data: Functio nal Compo nents	Missin g data: Availab le Compo nents	Missin g data: Functio nal Components	Missin g data: Availab le Compo nents	Missin g data: Functio nal Compo nents
Chronic	Condition	ıs							
Chroni	Beclom								
c	ethason								
asthma	e	0%	0%	0%	0%	0%	0%	0%	0%

	inhaler								
	Salbuta								
	mol	00/	00/	00/	00/	00/	00/	00/	00/
	inhaler	0%	0%	0%	0%	0%	0%	0%	0%
	Stethos	10/	10/	00/	00/	00/	00/	00/	00/
	cope	1%	1%	0%	0%	0%	0%	0%	0%
	At least								
	two								
	of: cal								
	cium								
	channel								
	blocker,								
	ACE								
	inhibito								
	r,								
	thiazide								
	, , , , ,								
	atenolol	00/		00/	00/	00/	00/	00/	00/
	D1 1	0%	0%	0%	0%	0%	0%	0%	0%
	Blood								
	pressure								
Hypert	apparat	407	- 0 /	00/	00/	00/	00/	00/	00/
ension	us	1%	7%	0%	0%	0%	0%	0%	0%
(stage 1	Stethos	101	407	00/		001			0.0 (
or 2)	cope	1%	1%	0%	0%	0%	0%	0%	0%
	Blood				7				
	glucose								
	test								
Type 1	equipm								
diabete	ent	2%	100%	0%	100%	0%	100%	0%	100%
s	Insulin	0%	0%	0%	0%	0%	0%	0%	0%
	Blood								
	glucose								
	test								
	equipm								
	ent	2%	100%	0%	100%	0%	100%	0%	100%
	Metfor								
Type 2	min or								
diabete	glibencl								
S	amide	0%	0%	0%	0%	0%	0%	0%	0%
Pain	Oral								
care	pain	0%	0%	0%	0%	0%	0%	0%	0%
Jui 0	Paris	575	370	<u> </u>	<u> </u>		<u> </u>	l	

	medicat								
	ion								
	Injectab								
	le								
	morphi			15%	15%	17%	17%	0%	0%
	ne or			1370	1370	1 / /0	1//0	070	070
	pethidin								
	e	99%	99%						
	At least								
	three of:								
	calcium								
	channel								
	blocker,								
	ACE								
	inhibito								
	r,thiazid								
Hypert	e,								
ension	atenolol	00/	224	00/	00/	00/	00/	00/	00/
requirin		0%	0%	0%	0%	0%	0%	0%	0%
g three	Blood								
or more	pressure								
antihyp	apparat			\bigcirc					
ertensiv	us	1%	7%	0%	0%	0%	0%	0%	0%
e	Stethos								
classes	cope	1%	1%	0%	0%	0%	0%	0%	0%
	Adult			•					
	scale	1%	7%	0%	2%	0%	2%	0%	0%
	Atenolo								
	1 or								
	other								
	beta-								
	blocker	0%	0%	0%	0%	0%	0%	0%	0%
	Blood	070	070	070	070	070	070	070	070
	pressure								
	apparat	10/	7%	00/	0%	0%	0%	0%	00/
	us	1%	/ 7/0	0%	U%0	U%0	U%0	U%0	0%
	Captopr								
	il,								
	enalapri								
	l or								
	other								
Heart	ACE								
failure	inhibito	0%	0%	0%	0%	0%	0%	0%	0%

	r								
	r								
	E								
	Furose mide	0%	0%	0%	0%	0%	0%	0%	0%
	Stethos	070	U%0	0%	0%	0%	0%	0%	0%
	cope	1%	1%	0%	0%	0%	0%	0%	0%
	Ultraso	1 /0	1 /0	070	070	070	070	070	070
	und								
	equipm								
	ent	99%	99%	15%	15%	17%	17%	0%	0%
	Benzath								
	ine								
	penicilli								
	n	0%	0%	0%	0%	0%	0%	0%	0%
	Injectab								
	le								
chronic	epineph								
RHD	rine	0%	0%	0%	0%	0%	0%	0%	0%
Acute Co	onditions								
	Functio								
	nal X-								
	ray								
	machine								
		99%	99%	15%	15%	17%	17%	0%	0%
	Oxygen								
	availabi								
	lity								
	(cylinde								
	r or								
	concent	1%	75%	0%	12%	0%	13%	0%	0%
	rator) Peak	1 70	1370	U70	1270	070	1370	U70	U70
	flow								
	meter in								
	NCD or								
	general								
	outpatie								
	nt area	100%	100%	100%	100%	100%	100%	100%	100%
Mild/m	Prednis								
oderate	olone	0%	0%	0%	0%	0%	0%	0%	0%
acute	Pulse								
Asthma	oximete								
	r	2%	84%	2%	8%	2%	8%	0%	0%


	Salbuta								
	mol								
	inhaler	0%	0%	0%	0%	0%	0%	0%	0%
	Functio								
	nal X-								
	ray								
	machine								
		99%	99%	15%	15%	17%	17%	0%	0%
	Oxygen								
	availabi								
	lity								
	(cylinde								
	r or								
	concent								
	rator)	1%	75%	0%	12%	0%	13%	0%	0%
	Peak								
	flow								
	meter in								
	NCD or								
	general								
	outpatie								
	nt area	100%	100%	100%	100%	100%	100%	100%	100%
	Prednis								
	olone	0%	0%	0%	0%	0%	0%	0%	0%
	Pulse				\mathcal{O}_{\cdot}				
	oximete			,					
	r	2%	84%	2%	8%	2%	8%	0%	0%
	Salbuta								
	mol								
	inhaler	0%	0%	0%	0%	0%	0%	0%	0%
	Micro								
	nebulize								
	r in								
	NCD or								
	general								
	outpatie	4.5.5.							
	nt area	100%	100%	100%	100%	100%	100%	100%	100%
Modera	Hydroc								
te/sever	ortisone								
e acute	injectio								
Asthma	n	0%	0%	0%	0%	0%	0%	0%	0%
Acute	Blood	60.	400		400	22:	400-		4005
diabete	glucose	2%	100%	0%	100%	0%	100%	0%	100%

S	test .								
	equipm								
	ent								
	Blood								
	pressure								
	apparat								
	us in								
	NCD or								
	general								
	outpatie								
	nt area	1%	7%	0%	0%	0%	0%	0%	0%
	Infusion								
	kit for								
	intraven								
	ous								
	fluids	11%	100%	6%	100%	6%	100%	0%	100%
	Injectab	11/0	10070	070	10070	070	10070	0,70	10070
	le								
	glucose								
	gracose	0%	0%	0%	0%	0%	0%	0%	0%
	т 1'								
	Insulin	0%	0%	0%	0%	0%	0%	0%	0%
	Liver								
	and								
	kidney								
	function								
	diagnos				4				
	tics								
	(creatini								
	ne,								
	electrol								
	ytes)	97%	97%	6%	6%	6%	6%	0%	0%
	Diazepa					4			
Acute	m								
epileps	injectio								
у	n	99%	99%	15%	15%	17%	17%	0%	0%
	Lidocai								
	ne in								
Injuries	minor								
/ acute	surgical								
minor	area	0%	0%	0%	0%	0%	0%	0%	0%
surgical	Nasoga								
conditi	stric								
ons+	tubes in	99%	99%	13%	23%	15%	25%	0%	0%
I		•		1	<u> </u>	1	1	1 * * * *	4 : 4

1								
minor								
surgical								
area								
Needle								
holder								
in								
minor								
surgical								
area	99%	99%	13%	15%	15%	17%	0%	0%
Oxygen								
availabi								
lity								
(cylinde								
r or								
concent								
rator)	1%	75%	0%	12%	0%	13%	0%	0%
Retracto								
r in								
minor								
surgical								
area	99%	99%	13%	15%	15%	17%	0%	0%
Scalpel								
in								
minor								
surgical								
area	99%	99%	13%	15%	15%	17%	0%	0%
Skin								
disinfec								
tant in								
minor								
surgical								
area	0%	0%	0%	0%	0%	0%	0%	0%
Surgical								
scissors								
in								
minor								
surgical								
area	99%	99%	13%	15%	15%	17%	0%	0%
Sutures								
in								
minor								
surgical								
area	0%	0%	0%	0%	0%	0%	0%	0%

Tourniq								
uet in								
minor								
surgical								
area	99%	99%	13%	31%	15%	31%	0%	25%





Appendix Figure 1. Spatial distribution of facilities in Malawi for a) PHCs and b) RSHs

Appendix Table 5: Service availability and service functionality for each essential medical component at PHCs and Secondary and Tertiary facilities

		PHC (n = 512)		Secondary and Tertiary Facilities (n=52)		
Condition	Essential Equipment & Medication	% Available	% Functional	% Available	% Functional	
Chronic Conditions						
	Service Readiness (SR)	-	8%	-	40%	
Chronic Asthma	Beclomethasone inhaler	9%	9%	42%	42%	
	Salbutamol inhaler***	71%	71%	88%	88%	
	Stethoscope	93%	92%	100%	100%	
	SR		34%		88%	

Hypertension (stage 1 or 2)	At least two of: calcium channel blocker, ACE inhibitor, thiazide, atenolol	37%	37%	88%	88%
	Blood pressure apparatus	93%	90%	100%	98%
	Stethoscope	93%	92%	100%	100%
	SR		5%		88%
Type 1 diabetes	Blood glucose test equipment	44%	NA	98%	NA
	Insulin	7%	6%	90%	90%
	SR		21%		94%
Type 2 diabetes	Blood glucose test equipment	44%	NA	98%	NA
	Metformin or glibenclamide	30%	30%	96%	96%
	SR		22%		29%
Pain care	Oral pain medication	100%	100%	100%	100%
	Injectable morphine or pethidine	21%	21%	31%	29%
	SR		15%		75%
Hypertension requiring three or more antihypertensive	At least three of: calcium channel blocker, ACE inhibitor,thiazide, atenolol	17.5%	17.5%	75%	75%
classes	Blood pressure apparatus	93%	90%	100%	98%
	Stethoscope	93%	92%	100%	100%
	SR		22%		38%
	Adult scale	98%	95%	98%	98%
Heart failure (RCH* only)	Atenolol or other beta-blocker	71%	71%	81%	79%
	Blood pressure apparatus	95%	93%	100%	98%

	Captopril, enalapril or other ACE inhibitor	67%	67%	75%	75%
	Furosemide	71%	71%	85%	85%
	Stethoscope	95%	93%	100%	100%
	Ultrasound equipment	33%	33%	83%	77%
	SR		7%		42%
Chronic RHD (RCH only)	Benzathine penicillin	78%	78%	83%	83%
,	Injectable epinephrine	31%	31%	58%	56%
Acute Condition	ns				
	SR		17%		50%
	Functional X-ray machine	34%	29%	83%	73%
	Oxygen availability (cylinder or concentrator)	85%	8%	88%	88%
Mild/moderate acute Asthma (RCH only)	Peak flow meter in NCD or general outpatient area**	NA	NA	NA	NA
	Prednisolone	73%	73%	88%	88%
	Pulse oximeter	61%	59%	92%	88%
	Salbutamol inhaler***	93%	93%	88%	88%
	SR		15%		44%
	Functional X-ray machine	33%	29%	83%	73%
Moderate/severe acute Asthma (RCH only)	Oxygen availability (cylinder or concentrator)	86%	86%	88%	88%
	Peak flow meter in NCD or general	NA	NA	NA	NA

	outpatient area **				
	Prednisolone	73%	73%	88%	88%
	Pulse oximeter	62%	60%	92%	88%
	Salbutamol inhaler***	93%	93%	88%	88%
	Micronebuliser in NCD or general outpatient area **	NA	NA	NA	NA
	Hydrocortisone injection	62%	62%	85%	85%
	SR		22%		65%
	Blood glucose test equipment	95%	NA	98%	NA
	Blood pressure apparatus in NCD or general outpatient area	95%	93%	100%	98%
Acute diabetic event (RCH	Infusion kit for intravenous fluids	88%	NA	92%	NA
only)	Injectable glucose	81%	81%	92%	92%
	Insulin	48%	48%	90%	90%
	Liver and kidney function diagnostics (creatinine, electrolytes)	45%	17%	85%	31%
Acute epilepsy (RCH only)	SR		36%		85%
	Diazepam injection	36%	36%	85%	85%
injuries/ acute minor surgical	SR		24%		46%


conditions+ (RCH only)	Lidocaine in minor surgical	95%	95%	98%	98%
	area				
	Nasogastric tubes				
	in minor surgical	67%	64%	77%	77%
	area				
	Needle holder in				
	minor surgical	90%	88%	85%	85%
	area				
	Oxygen				
	availability	86%	86%	88%	88%
	(cylinder or	8070	8070	0070	8670
	concentrator)				
	Retractor in				
	minor surgical	50%	50%	85%	85%
	area				
	Scalpel in minor	86%	83%	85%	85%
	surgical area	0070	0370	0370	0370
	Skin disinfectant				
	in minor surgical	86%	86%	87%	87%
	area				
	Surgical scissors				
	in minor surgical	89%	76%	85%	85%
	area				
	Sutures in minor	93%	90%	98%	98%
	surgical area	7370	7070	7070	7070
	Tourniquet in				
	minor surgical	57%	57%	69%	69%
	area				

^{*}RCH: Rural Community Hospital which is considered a higher level PHC facility

^{**}Data not available in 2019 HHFA.

^{***}Expected to be provided at primary level.

Appendix: Figure 2: Service readiness and service functionality for each essential medical component at PHCs and Secondary and Tertiary facilities - Chronic Conditions



Appendix: Figure 3: Service readiness and service functionality for each essential medical component at PHCs and Secondary and Tertiary facilities- Acute Conditions



BMJ Open

Service readiness for the management of noncommunicable diseases in publicly financed facilities in Malawi: findings from the 2019 Harmonized Health Facility Assessment census survey

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-072511.R1
Article Type:	Original research
Date Submitted by the Author:	05-Oct-2023
Complete List of Authors:	Ahmed, Sali; University of Washington, Department of Global Health Cao, Yanjia; The University of Hong Kong, Department of Geography Wang, Zicheng; Harvard University, T.H. Chan School of Public Health Coates, Matthew M.; Brigham and Women's Hospital, Department of Medicine Twea, Pakwanja; University of Bergen, Department of Global Health and Primary Care (IGS); Ministry of Health, Department of Planning and Policy Development Ma, Mingyang; Harvard University, Department of Biostatistics Chiwanda Banda, Jonathan; Ministry of Health, Curative and Medical Rehabilitation Services; Kamuzu University of Health Sciences, Department of Community and Environmental Health Wroe, Emily; Brigham and Women's Hospital, Department of Medicine Bai, Lan; Nanjing University of Traditional Chinese Medicine, Department of Public Administration Watkins, DA; University of Washington, Seattle, Department of Medicine; University of Washington Seattle Campus, Department of Global Health Su, Yanfang; University of Washington, School of Medicine
Primary Subject Heading :	Health policy
Secondary Subject Heading:	Health services research
Keywords:	Health Services Accessibility, Health Equity, Primary Health Care, Chronic Disease

SCHOLARONE™ Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Service readiness for the management of non-communicable diseases in publicly financed facilities in Malawi: findings from the 2019 Harmonized Health Facility Assessment census survey

Sali Ahmed ¹^, Yanjia Cao²^, Zicheng Wang ³^, Matthew M. Coates⁴, Pakwanja Twea^{5,6}, Mingyang Ma⁷, Jonathan Chiwanda⁸, Emily B. Wroe⁴, Lan Bai⁹, David A. Watkins^{1,10}, Yanfang Su^{1*}

- [1] Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA 98195
- [2] Department of Geography, The University of Hong Kong, Hong Kong SAR
- [3] Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115
- [4] Center for Integration Science in Global Health Equity, Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA, 02115
- [5] Bergen Centre for Ethics and Priority Setting, University of Bergen, Bergen, Norway
- [6] Department of Planning and Policy Development, Ministry of Health, Lilongwe, Malawi
- [7] Department of Biostatistics, Harvard University, Boston, Massachusetts, USA, 02115
- [8] Department of Clinical Services, Ministry of Health, Lilongwe, Malawi
- [9] Department of Public Administration, School of Health Economics and Management, Nanjing University of Traditional Chinese Medicine, Nanjing, China
- [10] Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, USA 98195

^Co-first authors

*Corresponding author

Sali Ahmed

salia@uw.edu

Zicheng Wang

zicheng wang@hsph.harvard.edu

Yanjia Cao

yanjiac@hku.hk

Matthew M. Coates

mmcoates@bwh.harvard.edu

Pakwanja Twea

pakwanja.twea@health.gov.mw

Mingyang Ma

mma@hsph.harvard.edu

Jonathan Chiwanda

tkins
tu jonchiwanda@gmail.com

Emily Wroe

ewroe@pih.org

Lan Bai

dreamhour@163.com

David A. Watkins

davidaw@uw.edu

Yanfang Su

yfsu@uw.edu

ABSTRACT

Introduction: Non-communicable diseases (NCDs) are rising in low-and middle-income countries (LMICs), including Malawi. To inform policymakers and planners on the preparedness of the Malawian healthcare system to respond to NCDs, we estimated NCD service readiness in publicly financed healthcare facilities in Malawi.

Methods: We analyzed data from 564 facilities surveyed in the 2019 Harmonized Health Facility Assessment (HHFA), including 512 primary health care (PHC) and 52 secondary and tertiary care (STC) facilities. To characterize service readiness, applying the law of minimum, we estimated the percentage of facilities where the equipment and medicines required to provide NCD services were functional. Further, we estimated permanently unavailable items to identify service readiness bottlenecks.

Results: Fewer than 40% of PHC facilities were ready to deliver services for any of the 13 NCDs analyzed. Insulin and beclomethasone inhalers had the lowest stock levels at PHC facilities (6% and 8%, respectively). Almost half of rural and community hospitals (RCHs) have never had insulin and benzathine penicillin (49% and 44%, respectively). STC facilities had varying service readiness, ranging from 27% for managing acute diabetes complications to 94% for chronic type 2 diabetes management. Only 38% of STC facilities were ready to manage heart failure. Oral pain medicines were widely available at all levels of health facilities; however, only 22% of RCH and 29% of STCs had injectable morphine or pethidine.

Conclusion: Publicly financed facilities in Malawi are generally unprepared to provide NCD services, especially at the PHC level. Targeted investments in PHC can substantially improve service readiness for chronic NCD conditions in local communities and enable STC to respond to acute NCD complications and more complex NCD cases.

Strengths and limitations of this study

- This study quantified non-communicable disease (NCD) service readiness critical to achieving universal health coverage (UHC) with a census sample of publicly financed facilities.
- Our approach provides generalizable results for all health facilities in Malawi.
- Our analyses by facility and service type can help planners better target investments to lagging areas.
- The analysis is limited to service-specific readiness and does not assess broader dimensions of health facility readiness, like human resources and basic infrastructure.
- The HHFA survey collects data on a subset of equipment and medicines required to manage NCDs and minor surgical conditions, constraining how service readiness is defined.

INTRODUCTION

Non-communicable diseases (NCDs) are responsible for 60% of early death and disability globally, and their growing burden in low- and middle-income countries (LMICs) is particularly concerning. According to the World Health Organization (WHO), 77% of the annual global NCD deaths occur in LMICs.(1) In 2021, NCDs caused 41 million deaths worldwide, among which 29 million died of the four major conditions, including cardiovascular disease (CVD), cancer, chronic respiratory disease, and diabetes. Several studies have reported low levels of NCD service readiness in LMICs.(2,3)

Located in Sub-Saharan Africa (SSA) with an 18.6 million population, Malawi remains one of the world's poorest countries, with a national Gross Domestic Product (GDP) of only \$645 per capita in 2022.(4) Malawi suffers from a high burden of NCDs and their economic consequences that affect the country's overall economic development and lead to catastrophic health expenditures (CHE) for many Malawians seeking care.(5–7) As of 2019, NCDs accounted for 40% of mortality in Malawi, an increase from 30% in 2010.(8)

Characterizing service readiness to manage NCDs in Malawi can help identify areas for investment to better respond to NCDs. Several prior studies provisionally assessed the preparedness of the Malawian healthcare system. A 2018 study analyzed data from the 2013-2015 Malawi Service Provision Assessment (SPA).(3) Another SPA-based study assessed the preparedness of first-referral level hospitals in eight low-income countries, including Malawi, and estimated the percentages of facilities with complete minimal sets of equipment and medicines needed for thirteen NCD conditions.(9) The results from these studies only presented assessments around 2015, when the SPA dataset was published.(3,9) A recent study estimated screening, diagnosis, management, and rehabilitation services readiness for NCDs based on a survey of 22 health facilities between 2019 and 2020.(10) The study employed a limited sample, which warrants caution in extrapolating the findings to all health facilities in Malawi. Having up-to-date and comprehensive information regarding health facilities' NCD service readiness in Malawi is essential for formulating evidence-informed health policies and judicious resource allocation. This study aims to fill a knowledge gap about service readiness for major NCD conditions using the most recent 2019 Harmonized Health Facility Assessment (HHFA) survey. This study has two main objectives. First, we estimate NCD service readiness by analyzing the availability and functionality of essential equipment and medicines to diagnose and treat common NCD conditions. Second, we identify potential bottlenecks that limit NCD service readiness.

METHODS

Study setting

Healthcare in Malawi is delivered through public, private for-profit (PFP), and private not-for-profit (PNFP) facilities.(11) The publicly-financed sector is intended to be universally accessible without payment at the point of care, while PFP and PNFP facilities are not open to everyone and only represent 11% of the facilities in the Malawian health system.(12,13) We focused our analysis on publicly financed facilities owned by the government and the Christian Health Association of Malawi (CHAM). The government is the leading healthcare provider in Malawi, while CHAM offers approximately 75% of healthcare services in remote and rural

areas.(14,15) Besides, in 2006, the government sought to enhance healthcare access for underserved rural populations by partnering with CHAM through a service legal agreement, wherein CHAM provides healthcare services at no cost to users and is later reimbursed by the government for the incurred service expenses.(15) The health system in Malawi is structured into primary, secondary, and tertiary levels. Primary care at health centers and rural community hospitals (RCH) offers ambulatory and maternity services. Secondary care includes first-referral (district) hospitals, while central hospitals constitute tertiary care.(11) Our analysis is disaggregated into PHC facilities (health centers and RCHs) and STC facilities (district and central hospitals) (Figure 1).

Data source

Our study analyzes the 2019 HHFA, funded by the WHO, the World Bank, and other collaborators. The HHFA is an update of the Service Availability and Readiness Assessment (SARA) survey, which was, in turn, built upon the SPA survey. The 2019 HHFA covered all publicly financed health facilities in the country. This survey adopted a census sample approach, covering all functional publicly financed facilities in Malawi (n=1098), of which 564 were owned by the Government and CHAM. The remaining facilities surveyed by the HFFA were owned by faith-based organizations other than CHAM and NGO-owned facilities falling under the private for-profit (PFP) and private not-for-profit (PNFP) categories. The HFFA assessed service readiness by asking whether the equipment and medicines required to provide different NCD services were available and functional.

Our analysis included all facilities that were supposed to provide NCD services and functioning during the survey. We removed one hospital, Zomba Mental Hospital, from our sample because it did not offer NCD services included in our analysis. According to the Administration of Health records, there were 485 registered health centers. However, only 471 of these were assessed by the HHFA. As a result, the 14 centers that were not surveyed were considered 'non-functional.'

The final sample we included in our analysis (n=564) consisted of 512 PHC facilities (471 health centers and 41 rural/community hospitals) and 52 STC facilities (48 district hospitals and 4 central hospitals (Appendix Table 1). The 48 district hospitals included actual district hospitals, large health centers functioning as quasi-district hospitals and first-referral-level CHAM hospitals. The spatial distribution of sampled facilities is displayed in Figure 1.

Data analysis

This study focused on the readiness of basic equipment and medicines to diagnose and treat five acute and seven chronic NCD conditions. The conditions included in the analysis are acute and chronic asthma, hypertension, heart failure, rheumatic heart disease (RHD), diabetes, epilepsy, injuries, and minor surgical conditions, and chronic pain (Appendix Table 2). Assessing the service availability for these conditions aligns with recommendations from the Disease Control Priorities Project and related publications on priority interventions for NCDs (16–19). The conditions included in our study are also prioritized in the Malawi Ministry of Health National Action Plan for NCD Prevention and Management 2017-2022.(20) We defined service readiness as having functional equipment and medicines stock to provide the NCD service in question. We considered equipment functional if it was operational and present in general outpatient or minor surgical areas. Medicines were considered "functional" if they were in stock, not expired, and appropriately stored in a manner that preserves the medicine's

potency.

Operational definitions and measures

Partners in the Ministry of Health advised us on the expected availability of NCD services at different levels of health facilities based on national guidelines and policies (Appendix Table 2). We extracted the corresponding indicators from the HHFA survey for analysis and examined data missingness to refine our indicator for each service. We detail the conditions, items, indicators, and related facility types in Appendix Table 3 and the missingness analysis in Appendix Table 4. When certain services were not expected to be offered at health centers, we only included rural/community hospital data in the denominator for those services' indicators.

Regarding missingness, the HHFA survey did not include questions on peak flow meters and micro-nebulizers required for asthma management in the outpatient setting. Therefore, we examined SPA data to understand how these missing variables might have affected the asthma readiness measure (Appendix Table 5). For the variables with close to 100% missing data, we assumed that the item was not expected to be available at the facility level.

The HHFA survey classifies medicines or equipment as "available and functional," "available but not functional," "not available (at this time)," or "never available" at the facility. Accordingly, we calculated three indicators: 1) functionality, 2) permanent unavailability, and 3) service readiness.

Functionality: Functionality refers to the presence of the functioning items (equipment and stock of medicines, not expired and properly stored) involved in providing a given NCD service.

```
Functionality = \frac{number\ of\ facilities\ with\ available\ and\ functioning\ item}{Total\ number\ of\ facilities}
```

Service readiness: For each facility, we estimated service readiness based on the functionality of the set of basic items required to provide a given NCD service.

Permanent unavailability: Permanent unavailability is when the item (medicine or equipment) is never present at the health facility, i.e., not temporarily unavailable due to supply issues.

```
Permanent\ unavailability\ = \frac{number\ of\ facilities\ with\ items\ that\ were\ never\ present}{Total\ number\ of\ facilities}
```

When a facility had all essential components available and functioning, it was labeled "ready" to provide that service. Otherwise, the facility was labeled as "Not ready."

Applying Carl Sprengel's Law of the Minimum, this study likens service readiness to an organism's growth.(21) We pinpoint the limiting factor impeding readiness, analogous to the lowest point in a barrel regulating water level (Figure 2). This method guarantees a robust service readiness assessment, as absent data on non-limiting factors does not bias the results. However, if data on the limiting factor is missing, service readiness may be overestimated, as seen in the difference between the complete and incomplete barrels in Figure 2.

Patient and public involvement

None.

RESULTS

We included 564 facilities (i.e., 512 PHC facilities and 52 STC facilities) in our analysis.

There were 14 non-functioning health centers and one specialized tertiary hospital excluded from our analysis. Based on the Ministry of Health guidelines and missing data, we assumed that the following services were not expected to be delivered at health centers: chronic heart failure care, chronic rheumatic heart disease care, treatment of acute asthma exacerbations, acute complications of diabetes, acute epilepsy (seizures), and injuries (Appendix Table 2). Except for the missing data on conditions at health centers, all other variables had less than 25% missing data (Appendix Table 4).

NCD service readiness Figure 3 compares the service readiness of PHC and STC facilities for chronic and acute NCD services. Overall, the readiness of STC facilities was higher than PHCs. We found that the service readiness was lower than 40% for NCD services at PHC facilities. Among the chronic NCD services, PHC facilities were least ready to provide services for type 1 diabetes and chronic asthma (5% and 8%, respectively). Among the acute services included in the analysis, RCHs were least ready to manage acute complications of diabetes (12%), acute asthma exacerbations (less than 20%), and injuries/acute minor surgical conditions (24%). PHCs had higher readiness scores for managing acute epilepsy (among RCH in PHC estimation) and stage 1 and 2 hypertension. STC facilities were near full readiness for type 2 diabetes (94%), type 1 diabetes (88%), stage 1 and 2 hypertension (88%), and acute epilepsy treatment (85%). However, STC facilities were least ready to provide care for acute complications of diabetes (27%) and had relatively lower readiness for managing chronic asthma, pain, heart failure, rheumatic heart disease, moderate/severe acute asthma, and injuries/ acute minor surgical conditions.

Equipment functionality and Medicine stock

Figure 4 shows the functionality of equipment and medicines stock required to provide the 13 services we included in the analysis. Insulin for type 1 diabetes and beclomethasone inhalers for managing chronic asthma had the lowest stock at the PHC level (6% and 8%, respectively). Around 90% of STCs had insulin, but beclomethasone inhalers show low stock (42%) at STC health facilities. Availability of antihypertensives is low in PHC facilities, with only 16% having "at least three or more antihypertensive classes" of medication and only 37% having at least two, compared to 75% and 88% in STC facilities. The availability of functional diagnostic equipment was limited, even in RCHs. For example, functional X-ray machines were found in only 29% of the RCHs, and ultrasound was functional in 34%.

Additionally, only 46% of RCH stock insulin for managing acute complications of diabetes, compared to 90% of STC facilities. However, RCH and STC facilities had low availability of functioning diagnostic tests required to manage acute complications of diabetes. Liver and kidney function tests were functional in only 17% of the RCH and 31% of STC facilities.

Permanently unavailable items

As shown in Figure 5, beclomethasone was a "bottleneck item" for chronic asthma service readiness at all levels since it was never available at 74% of PHC and 29% of STC facilities. Basic medicines for managing type 1 and 2 diabetes and acute complications of diabetes were bottleneck items for diabetes care readiness at PHC facilities. For chronic rheumatic heart disease management, 44% of RCH did not have benzathine penicillin. However, Figure 5 also shows that there were items consistently in stock. These include oral pain medicines, salbutamol inhalers, and diazepam injections, among others.

DISCUSSION

Our analysis reveals significant gaps and disparities in the readiness of health facilities to respond to the growing burden of NCDs in Malawi. Fewer than 40% of PHCs are ready to diagnose and manage any of the 13 NCD services included in the analysis. Although STC facilities had higher readiness scores, 50% or fewer were not ready to diagnose and treat conditions like acute diabetes events, asthma, injuries/minor surgeries, chronic heart failure, chronic rheumatic heart disease, and pain. PHCs were least ready with basic equipment and medicines to manage type 1 diabetes and chronic asthma (less than 10%) and were most ready to treat acute epilepsy (37%). PHCs had higher readiness to manage Stage 1 and 2 hypertension (34%) but were less ready to treat complicated hypertension requiring three or more antihypertensive classes.

Our findings are consistent with prior studies that illustrate an urgent need to invest more in health systems across sub-Saharan Africa, including Malawi, to respond to NCDs.(3,9,10) In line with previous analyses, we found notable gaps and limited readiness to manage NCDs, particularly in PHC facilities.(3,10,22) Analysis of 2013-2015 SPA data for primary, secondary, and tertiary level facilities in Malawi showed that only 37.7% of PHC facilities were ready to provide services for diabetes, Chronic Respiratory Disease, and CVD compared to 96% of STC facilities.(3) Compared to the 2013-2015 SPA analysis of 43 first-referral level facilities, chronic asthma service readiness had increased to 40% in STC facilities compared to 5% in 2015.(9) STC facility readiness to manage type 1 and 2 diabetes increased from around 40% to 90%. Readiness for managing hypertension stages 1 and 2 increased from 44% to 88%, while services for hypertension requiring three or more antihypertensive classes increased from 26% to 75%. Readiness of STC facilities increased from 12% to 38% for chronic heart failure and from 9% to 42% for chronic rheumatic heart disease, but there was no increase in readiness for managing acute complications of diabetes. Service readiness for acute epilepsy and pain care decreased from 95% to 85% and 58% to 29%, respectively.

The deficiencies in NCD services are not unique to Malawi. Studies analyzing SPA data revealed low readiness of NCD services in countries like Tanzania, Singal, and Ethiopia.(3,9) Additional cross-sectional surveys to assess NCD services readiness revealed a similar pattern in Zambia but slightly higher readiness scores in Kenya, but the difference might stem from the dissimilarity in the service readiness calculation method.(22,23) Also, a systematic analysis of survey data focused on diabetes in sub-Saharan Africa reported low diagnostic capacity and supply of diabetes medicines in 14 African countries.(24)

Our analysis revealed a number of bottleneck items for NCD care in Malawi, including beclomethasone inhalers. Asthma management is not part of the NCD intervention package included in the essential health package of Malawi, and the Standard Treatment Guidelines for Malawi state that beclomethasone is only expected to be provided at the tertiary level.(25,26) However, the WHO considers beclomethasone as an essential and cost-effective intervention for chronic asthma care that can be provided at PHC facilities.(27,28) Our study suggests that the 2015 Standard Treatment Guidelines for Malawi could be revised to align with WHO recommendations, ensuring better access to asthma care in the community.

Addressing NCDs is a critical component of the health-related SDGs.(19)The essential health package developed by the Ministry of Health specified that management of diabetes, hypertension, and injuries be provided at primary and secondary facilities.(26) Unfortunately, our study shows that most PHC facilities had low service readiness for these services and others. The Ministry of Health has acknowledged concerns about the suboptimal implementation of the Essential Health Package due to inadequate resources, low awareness among stakeholders,

and the lack of clear financial mechanisms to ensure the provision of free-of-charge services at the point of care. To make progress on NCDs, the Ministry will need to explore options for increasing healthcare financing in a manner that will benefit the entire range of healthcare needs, including NCDs.

This study has several limitations. Notably, our definition of service readiness is constrained by the methodology used in the HHFA survey, which focuses on a specific subset of equipment and medicines. This can introduce bias depending on the criteria and items used to define service readiness. For example, as the HHFA survey does not assess the availability of the nebulizers and peak flow meter in the outpatient departments, we did not include them as part of the essential equipment required for treating acute asthma. To address this, we analyzed 2013-2015 SPA data to understand potential bias in our estimates. Data from the 2013-2015 SPA survey about the peak flow meter suggests that we may have overestimated the service readiness for acute asthma (Appendix Table 5). While availability may have grown since 2015, if availability remains unchanged, it may be an alarming limiting factor for the overall readiness for acute asthma care. Second, the HHFA covers a limited range of health conditions and potential services for NCDs. We recommend that the WHO continue refining the HHFA survey to enhance the scope and precision of indicators for essential healthcare.

Additionally, the scope of our analysis is limited to service-specific readiness for a few NCDs and does not assess broader dimensions of health facility readiness, like human resources and basic infrastructure. A study by Banda et al.(10) of a smaller number of health facilities assessed other dimensions not included in the HHFA survey, such as whether facilities kept reliable records for NCD patients, supplemented with qualitative interviews to characterize the constraints.

CONCLUSION

Our analysis reveals that, despite progress since 2015, health facilities in Malawi have a long way to go to ensure universal access to NCD services. Despite being the first point of care and the ideal platform for early detection and long-term management of most NCDs, PHC facilities in Malawi have low NCD service readiness. While health centers and rural/community hospitals may not be expected to perform complete diagnostics or treatment for complicated conditions, these primary care facilities are well-positioned to provide basic services for common NCDs. PHC facilities urgently need additional investment to improve NCD service availability. For other NCDs, a progressive approach to decentralizing NCD care would start by building the capacity of RCH that, over time, could allow for extending a broader range of services to PHC facilities. Our list of bottlenecks and permanently unavailable items provides a starting point to enhance the supply of medicines and equipment. The list can also inform the updating of guidelines to achieve better service readiness for particular conditions sensitive to these identified bottlenecks.

Contributors

ZW, YC, and SA led the literature review and wrote the first draft of the manuscript. PT and JC provided data and supporting documents. ZW and LB analyzed the data, and MM replicated the estimates. ZW and MM produced the tables. YS, YC, and SA created the figures. MC, PT, EW, and DW contributed to conceiving the study, refining the methods, and interpreting the results. DW acquired funding for the research. YS led the study design, method development, and result interpretation. All the authors have made significant intellectual or practical contributions, critically revised the manuscript, and approved the final version of this paper.

Competing interests

We declare that none of the authors nor coauthors have any financial or non-financial competing interests that may influence the analysis or the interpretation of this paper.

Funding

This work was supported by the Bergen Centre for Ethics and Priority Setting (BCEPS) with support from the Trond Mohn Foundation and the Norwegian Agency for Development Cooperation (NORAD), project number 874 789 542.

Data availability statement

The data supporting this study's findings were obtained through the MoH Malawi and are not available in a public repository.

Ethics approval

As this study was an analysis of an existing dataset, review and approval by an IRB was not required.

Acknowledgments

The authors thank the Ministry of Health in Malawi. We are thankful for the replication of results by Jiashuo Sun and graphic design by Lisa Fox, Meranda Wang, Jingning Wang, and Ella Shi. We are also grateful for all the valuable comments from Simon Ding, editors and reviewers.

References

- 1. World Health Organization. Noncommunicable disease [Internet]. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
- 2. Leslie HH, Spiegelman D, Zhou X, Kruk ME. Service readiness of health facilities in Bangladesh, Haiti, Kenya, Malawi, Namibia, Nepal, Rwanda, Senegal, Uganda and the United Republic of Tanzania. Bull World Health Organ. 2017 Nov 1;95(11):738–48.
- 3. Moucheraud C. Service Readiness For Noncommunicable Diseases Was Low In Five Countries In 2013–15. Health Aff (Millwood). 2018;37(8).
- 4. The World Bank. The World Bank Data Malawi [Internet]. 2022. Available from: https://data.worldbank.org/country/MW
- 5. Kim ET, Singh K, Speizer IS, Angeles G, Weiss W. Availability of health facilities and utilization of maternal and newborn postnatal care in rural Malawi. BMC Pregnancy Childbirth. 2019 Dec 17;19(1):503.
- 6. Macarayan EK, Gage AD, Doubova SV, Guanais F, Lemango ET, Ndiaye Y, et al. Assessment of quality of primary care with facility surveys: a descriptive analysis in ten low-income and middle-income countries. Lancet Glob Health. 2018 Nov 1;6(11):e1176–85.
- 7. Wang Q, Brenner S, Kalmus O, Banda HT, De Allegri M. The economic burden of chronic non-communicable diseases in rural Malawi: an observational study. BMC Health Serv Res. 2016 Sep 1;16(1):457.
- 8. Wroe EB, Kalanga N, Dunbar EL, Nazimera L, Price NF, Shah A, et al. Expanding access to non-communicable disease care in rural Malawi: outcomes from a retrospective cohort in an integrated

- NCD-HIV model. BMJ Open. 2020 Oct;10(10):e036836.
- 9. Gupta N, Coates MM, Bekele A, Dupuy R, Fénelon DL, Gage AD, et al. Availability of equipment and medications for non-communicable diseases and injuries at public first-referral level hospitals: a cross-sectional analysis of service provision assessments in eight low-income countries. BMJ Open. 2020 Oct;10(10):e038842.
- 10. Banda CK, Hosseinipour MC, Kumwenda J, Banda NPK, Lutala P, Makwero M, et al. Systems Capacity To Conduct Non-Communicable Disease Focused Implementation Research In The Malawian Health Sector: A National Needs Assessment [Internet]. In Review; 2021 May [cited 2021 Nov 23]. Available from: https://www.researchsquare.com/article/rs-496152/v1
- 11. MOH, Malawi. Health Care System [Internet]. 2016 [cited 2022 Dec 12]. Available from: https://www.health.gov.mw/index.php/2016-01-06-19-58-23/national-aids
- 12. Makwero MT. Delivery of primary health care in Malawi. Afr J Prim Health Care Fam Med. 2018;10(1):e1–3.
- 13. World Health Organization. Malawi: Country Cooperation Startegy at a glance [Internet]. 2018. Available from: http://apps.who.int/iris/bitstream/handle/10665/136935/ccsbrief_mwi_en.pdf;jsessionid=6622A9B 77AC48437784A63B1C127472E?sequence=1
- 14. Zeng W, Sun D, Mphwanthe H, Huan T, Nam JE, Saint-Firmin P, et al. The impact and cost-effectiveness of user fee exemption by contracting out essential health package services in Malawi. BMJ Glob Health. 2019 Apr;4(2):e001286.
- 15. Mchenga M, Manthalu G, Chingwanda A, Chirwa E. Developing Malawi's Universal Health Coverage Index. Front Health Serv [Internet]. 2022 [cited 2023 Sep 30];1. Available from: https://www.frontiersin.org/articles/10.3389/frhs.2021.786186
- 16. Watkins D, Jamison D, Mills A, Atun R, Danforth K, Glassman A, et al. "Universal Health Coverage and Essential Packages of Care". In: Disease Control Priorities (third edition): Volume 9, Disease Control Priorities, edited by D. T. Jamison, H. Gelband, S. Horton, P. Jha, R. Laxminarayan, C. N. Mock, R. Nugent. Washington, DC: World Bank. [Internet]. [cited 2023 Jul 14]. Available from: https://dcp-3.org/chapter/2551/essential-universal-health-coverage
- 17. Prabhakaran D, Anand S, Watkins D, Gaziano T, Wu Y, Mbanya JC, et al. Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition. The Lancet. 2018 Mar 24;391(10126):1224–36.
- 18. Annex 3C. Essential Universal Health Coverage: Interventions and Platforms. Supplementary material for: Watkins, DA, DT Jamison, A Mills, R Atun, K Danforth, and others. 2018. "Universal Health Coverage and Essential Packages of Care." In Disease Control Priorities: Improving Health and Reducing Poverty edited by DT Jamison, H Gelband, S Horton, P Jha, R Laxminarayan, CN Mock, and R Nugent. Volume 9 of Disease Control Priorities, third edition. Washington, DC: World Bank. Available from: http://dcp-3.org/sites/default/files/chapters/Annex%203C_Interventions%20in%20EUHC.pdf
- 19. Cardiovascular, Respiratory, and Related Disorders | DCP3 [Internet]. [cited 2023 Jul 14]. Available from: https://dcp-3.org/cvd
- MOH Republic of Malawi. National Action Plan for the Prevention and Management of Non-Communicable Diseases in Malawi. 2017; Available from: https://www.iccpportal.org/system/files/plans/MWI_B3_s21_Malawi%20NCD%20Strategy_2018.pdf

- 21. Tang J, Riley WJ. Finding Liebig's law of the minimum. Ecol Appl. 2021;31(8):e02458.
- 22. Shiroya V, Shawa N, Matanje B, Haloka J, Safary E, Nkhweliwa C, et al. Reorienting Primary Health Care Services for Non-Communicable Diseases: A Comparative Preparedness Assessment of Two Healthcare Networks in Malawi and Zambia. Int J Environ Res Public Health. 2021 May 10;18(9):5044.
- 23. Ammoun R, Wami WM, Otieno P, Schultsz C, Kyobutungi C, Asiki G. Readiness of health facilities to deliver non-communicable diseases services in Kenya: a national cross-sectional survey. BMC Health Serv Res. 2022 Aug 2;22:985.
- 24. Nuche-Berenguer B, Kupfer LE. Readiness of Sub-Saharan Africa Healthcare Systems for the New Pandemic, Diabetes: A Systematic Review. J Diabetes Res. 2018 Feb 18;2018:e9262395.
- 25. Ministry of Health, Malawi. Malawi Standard Treatment Guidelines Essential Medicines List 2015.pdf [Internet]. 2015 [cited 2022 Dec 12]. Available from: https://extranet.who.int/ncdccs/Data/MWI_D1_Malawi-Standard-Treatment-Guidelines-Essential-Medicines-List-2015.pdf
- 26. MOH Republic of Malawi. Health Sector Strategic Plan II, Towards Universal Health Coverage. 2017; Available from: https://www.health.gov.mw/downloads/
- 27. World Health Organization. 2008-2013 action plan for the global strategy for the prevention and control of noncommunicable diseases: prevent and control cardiovascular diseases, cancers, chronic respiratory diseases and diabetes. Plan Action 2008-2013 Pour Strat Mond Lutte Contre Mal Non Transm. 2009;42.
- 28. World Health Organization. Prevention and control of noncommunicable diseases: guidelines for primary health care in low resource settings [Internet]. Geneva: World Health Organization; 2012 [cited 2022 Dec 12]. 68 p. Available from: https://apps.who.int/iris/handle/10665/76173

FIGURE LEGENDS

Figure 1. Healthcare systems in Malawi

The figure presents the structure of the health system in Malawi and maps the health facilities in the country.

Figure 2. Required items and service readiness relation

The figure presents the relationship between service readiness (water level) and complementary items (bars).

Figure 3. NCD service readiness of the Malawi health system by level

The figure presents the service readiness of chronic and acute NCD conditions, comparing PHC Level to STC Level.

Figure 4. Service functionality for each essential medical component at PHCs and STC

facilities

The figure illustrates the availability of essential equipment and medicines considered in the analysis, categorizing them into equipment and medicine.

Figure 5. Permanent unavailability by facility level

The figure presents the items that were never available, comparing the PHC and STC levels.






Figure 1. Healthcare system and facilities in Malawi $152 \times 148 \text{mm} \ (300 \times 300 \text{ DPI})$






Figure 2: Required items and service readiness relation $207x121mm (300 \times 300 DPI)$








Figure 4: Functionality and stock of essential equipment and medicines at PHCs and STC facilities.

213x202mm (300 x 300 DPI)

Condition		Equipment & Medicines	РНС	STC	
	Chronic	Beclomethasone inhaler	74%	29%	
	Asthma	Salbutamol inhaler	8%	0%	
	HTN (Stage 1 or 2)	>=2 of: CCB, ACEI, thiazide, atenolol	12%	0%	
	Type 1 diabetes	Insulin	81%	2%	
	Type 2 diabetes	Metformin/ glibenclamide	48%	0%	
Chronic	Oral pain care	Oral pain medication	0%	0%	
Conditions	Injectable pain care *	Injectable morphine/pethidine	7%	19%	
		Atenolol or other beta- blocker	24%	6%	
	Chronic heart failure*	Captopril, enalapril or other ACEI	20%	6%	
		Furosemide	12%	2%	
	Chronic	Benzathine penicillin	44%	8%	
	RHD*	Injectable epinephrine	5%	10%	
	moderate	Prednisolone	10%	0%	
	acute	Salbutamol inhaler	0%	0%	
		Prednisolone	10%	0%	
	Moderate/ severe acute	Salbutamol inhaler	0%	0%	
Acute	asthma*	Hydrocortisone injection	32%	8%	
Conditions	Acute diabetic	Injectable glucose	0%	2%	
	events*	Insulin	49%	2%	
	Acute epilepsy*	Diazepam injection	0%	0%	
	Injuries/	Lidocaine	2%	0%	
	acute minor surgical	Skin disinfectant	5%	2%	
	conditions*	Sutures	5%	0%	

Appendix Table 1. Summary of publicly financed facility representation in each category

	Primary health care (PHC) facilities			Secondary and tertiary care (STC) facilities		
Facility type	Health centers	Rural/Co mmunity hospitals (RCH)	Total	District hospitals	Central hospitals	Total
Total facilities	485	41	526	48	5	53
Non- functiona l facilities*	14	0	14	0	0	0
HHFA samples	471**	41	512	48	4	52

^{*}We consider the facilities not surveyed by the HHFA as "non-functional" because HHFA is a census survey.

^{**}Three quasi-district hospitals were categorized as "District Hospitals": Ndirande Health Centre, Matawale Health Centre, and Mzuzu Health Centre.

Appendix Table 2: NCD services analyzed by expected level of service

Condition		ry health care	Secondary and tertiary	
		facilities	facilities	
	Health	Rural/Community		Central
	Centers	Hospitals	Hospitals	Hospitals
Controlled chronic				
conditions				T
Chronic asthma	X	x	X	х
Hypertension (stage 1 or				
2)	X	X	X	х
Type 1 diabetes	X	x	X	х
Type 2 diabetes	X	x	X	х
Oral pain care	X	х	X	х
Injectable pain care	5	X	X	X
Hypertension requiring				
three or more				
antihypertensive classes	х	X	X	Х
Heart failure		x	X	х
Chronic RHD		x	X	x
Acute exacerbations and c	omplication	18		
Mild/moderate acute				
Asthma		x	Х	х
Moderate/severe acute		4		
Asthma		x	Х	х
Acute diabetic events		х	х	х
Acute epilepsy		х	x	х
injuries/ acute minor				
Surgical conditions+		X	X	х

Appendix Table 3: Service Indicators

Part 1: Acute conditions

Part 1: Acute co	hiulions		1	I	T
diseases	Essential	Availability	Functionality	"Never	Facility Types
	equipment and	Indicators	Indicators	Available"	Surveyed*
	medications			Data	
				Availability	
Mild/moderate	Functional X-ray	T125_01	$T125_01 (Y = 1;$	No Data	1,2,3
acute Asthma	machine	(Y = 1,2,3; N =	N = 2,4,NA		
		4,NA)			
	Oxygen	HH101 22 (Y =	HH101А22 (Y	No Data	1,2,3,4
	availability	"Yes", N = "No",	= "Yes", N =		
	(cylinder or	NA) OR	"No", NA) OR		
	concentrator)	HH101 23	HH101A23 (Y		
		(cylinder) (Y =	,		
		"Yes", N = "No",			
		NA)			
		No Data (used	No Data	No Data	No Data
		SPA data for			
		estimation)			
	outpatient area				
	-	U103 10 ($Y = 1$,	U103 10 (Y =	U103 10 ==	1 2 3 4
		2; N = 3,4,5,NA)	_ `	_	1,2,3,1
			2,3,4,5,NA)		
	Pulse oximeter	HH101 8 (Y =		No Data	1,2,3,4
		"Yes", N = "No",			1,2,3,4
			"No", NA)		
		$U103_21 (Y =$		II103 21 ==	1 2 3 1
		1,2; N =			1,2,3,4
		3,4,5,NA)		3	
Moderate/gave		T125 01		No data	1,2,3
		(Y = 1,2,3; N =	_ ` ′	No data	1,2,3
re acute Asthma		<u> </u>	N = 2,4,NA		
Asuma		4,NA)			
		IIII 01 00 07	THE 101 A 22 (X	NT 1	1 2 2 4
	""	HH10122 (Y =	`		1,2,3,4
		"Yes", N = "No",			
	` •	1	"No", NA) OR		
			HH101A23 (Y		
		(cylinder) $(Y =$,		
		"Yes", N = "No",	"No", NA)		
		NA)			
		No Data (used	No data	No data	No data
		SPA data for			
	general	estimation)			

	outpatient area		
	Prednisolone	U103 10 (Y = 1,U103 10 (Y = U103 10 ==	1,2,3,4
		$\begin{bmatrix} -1 & -1 & -1 \\ 2; N = 3,4,5,NA \end{bmatrix}$ 1; $\begin{bmatrix} -1 & -1 \\ N & = 5 \end{bmatrix}$, ,-,
		2,3,4,5,NA)	
	Pulse oximeter		1,2,3,4
		"Yes", N = "No", "Yes", N =	, ,-,
		NA) "No", NA)	
	Salbutamol	U103_21 (Y = U103_21 (Y = U103_21 ==	1,2,3,4
	inhaler	1,2; N = $ 1;$ N = $ 5 $	
		3,4,5,NA) 2,3,4,5,NA)	
	Micro nebuliser	No Data (used No Data No Data	No Data
	in NCD or	SPA data for	
	general	estimation)	
	outpatient area		
	Hydrocortisone	$U103_{11}$ (Y = $U103_{11}$ (Y = $U103_{11}$	1,2,3,4
	injection	1,2; N =1; N ==5	
		3,4,5,NA) 2,3,4,5,NA)	
Acute diabetes	Blood glucose	T105_01 (Y = No Data No Data	1,2,3,4
	test equipment	1,2; N = 3,NA)	
	Blood pressure	HH10115 (Y = HH101A15 (YNo Data	1,2,3,4
	apparatus in	"Yes, N == "Yes", N =	
	NCD or general	"No",NA) "No",NA)	
	outpatient area		
	Infusion kit for	M116_161(Y = No Data No Data	1,2,3,4
	intravenous	"Yes", N = "No")	
	fluids	4	
	Injectable	$U103_03 \text{ (Y = } U103_03 \text{ (Y = } U103_03 \text{ ==}$	1,2,3,4
	glucose	1,2; N =1; N =5	
		3,4,5,NA) 2,3,4,5,NA)	
	Insulin	$U103_02 (Y = U103_02 (Y = U103_02)$	1,2,3,4
		1,2; N =1; N ==5	
		3,4,5,NA) 2,3,4,5,NA)	
	Liver and kidney	$T113_03$ (Y = $T123_01$ (Y = 1; $T123_01$	1,2,3
	function	1,2; N = 3,NA) $N = 2,3,4,NA) = -5$	
	diagnostics	Or T122_01 (Y =	
	(creatinine,	1,2; N =3,NA) Or	
	electrolytes)	T123_01 (Y =	
		1,2,3; N = 4,NA)	
Acute	Diazepam	U125_16 (Y = U125_16 (Y = U125_16	All facility types
epilepsy	injection	1,2; N = 1; N = -5 And	AND
		3,4,5,NA) or 2,3,4,5,NA) Or U126_05	M103.Yes.Conta
		U126_05 (Y = U126_05 (Y ===5	ins(8)

Nasogastric tubes RR115_7 (Y = RR115A7 (Y = No Data in minor surgical "Yes", N = "No", "Yes", N = area NA) "No", NA) Needle holder in RR115_3 (Y = RR115A3, (Y = No Data minor surgical "Yes", N = "No", "Yes", N = area NA) "No", NA) Oxygen HH101_22 (Y = HH101A22 (Y No Data availability "Yes", N = "No", "No", NA) Retractor in RR115_5 (Y = RR115A5 (Y = No Data ninor surgical "Yes", N = "No", "Yes", N = "No", "No", NA)) Scalpel in minor RR115_4 (Y = RR115A4 (Y = No Data ninor surgical ninor ni					
Injuries/ acute Lidocaine in U125_12 (Y = U125_12 (Y = U125_12 1,2,3,4 minor surgical minor surgical 1,2; N1; N ===5 1,2,3,4 minor surgical minor surgical 1,2; N1; N ===5 1,2,3,4 minor surgical minor surgical 1,2; N1; N ===5 1,2,3 min minor surgical minor minor surgical minor			1,2; N =	1; N =	
minor surgical minor surgical 1,2;			3,4,5,NA)	2,3,4,5,NA)	
Seconditions Area	Injuries/ acute	Lidocaine in	$U125_12 (Y =$	$U125_{12} (Y = U125_{12})$	1,2,3,4
Nasogastric tubes RR115_7 (Y = RR115A7 (Y = No Data in minor surgical "Yes", N = "No", "Yes", N = area	minor surgical	minor surgical	1,2; N	1; N ===5	
in minor surgical "Yes", N = "No", "Yes", N = area	conditions+	area	=3,4,5,NA)	2,3,4,5,NA)	
Area NA "No", NA Needle holder in RR115_3 (Y = RR115A3,(Y = No Data minor surgical "Yes", N = "No", "Yes", N = area NA "No", NA		Nasogastric tubes	RR115_7 (Y =	RR115A7 (Y = No Data	1,2,3
Needle holder in RR115_3 (Y = RR115A3,(Y = No Data 1,2,3 minor surgical "Yes", N = "No", "Yes", N = area NA) "No", NA)		in minor surgical	"Yes", N = "No",	"Yes", N =	
minor surgical "Yes", N = "No", "Yes", N = area NA) "No", NA) Oxygen HH101_22 (Y = HH101A22 (YNo Data availability "Yes", N = "Yes", N = "Yes", N = (cylinder or NA) OR "H1101_23 HH101A23 (Y (cylinder) (Y = "Yes", N = "No", "No", NA) Retractor in RR115_5 (Y = RR115A5 (Y = No Data nor surgical "Yes", N = "No", "Yes", N = area nor nor surgical "Yes", N = "No", "Na)) Scalpel in minor RR115_4 (Y = RR115A4 (Y = No Data nor		area	NA)	"No", NA)	
area NA) "No", NA) Oxygen HH101_22 (Y = HH101A22 (YNo Data availability "Yes", N = "Yes", N = "Yes", N = (cylinder or NA) OR "No", NA) OR HH101_23 HH101A23 (Y (cylinder) (Y = "Yes", N = "No", "No", NA) Retractor in RR115_5 (Y = RR115A5 (Y = No Data nor surgical "Yes", N = "No", NA)) Scalpel in minor RR115_4 (Y = RR115A4 (Y = No Data nor		Needle holder in	$RR115_3 (Y =$	RR115A3,(Y = No Data	1,2,3
Oxygen		minor surgical	"Yes", N = "No",	"Yes", N =	
availability (cylinder or NA) OR "No", NA) OR (cylinder or NA) OR "No", NA) OR HH101_23 HH101A23 (Y (cylinder) (Y == "Yes", N = "Yes", N = "No", "No", NA) Retractor in RR115_5 (Y =RR115A5 (Y = No Data minor surgical "Yes", N = "No", "Yes", N = area NA)) Scalpel in minor RR115_4 (Y =RR115A4 (Y = No Data surgical area "Yes", N = "No", "Yes", N = NA)) Skin disinfectant U125_05 (Y = U125_05 (Y = U125_05 in minor surgical 1,2; N = 1, N ==5 area 3,4,5,NA) Surgical scissors RR115_6 (Y = RR115A6 (Y = No Data in minor surgical "Yes", N = "No", "Yes", N = area NA) Surgical scissors RR115_6 (Y = RR115A6 (Y = No Data in minor surgical "Yes", N = "No", "Yes", N = area NA) Sutures in minor U125_09 (Y = U125_09 (Y = U125_09 in No", NA) Sutures in minor U125_09 (Y = U125_09 (Y = U125_09 in No", NA) Surgical area 1,2; N = 3,4,5) 1; N = 2,3,4,5) ==5		area	NA)	"No", NA)	
availability (cylinder or NA) OR "No", NA) OR (cylinder or NA) OR "No", NA) OR HH101_23 HH101A23 (Y (cylinder) (Y == "Yes", N = "Yes", N = "No", "No", NA) Retractor in RR115_5 (Y =RR115A5 (Y = No Data minor surgical "Yes", N = "No", "Yes", N = area NA)) Scalpel in minor RR115_4 (Y =RR115A4 (Y = No Data surgical area "Yes", N = "No", "Yes", N = NA)) Skin disinfectant U125_05 (Y = U125_05 (Y = U125_05 in minor surgical 1,2; N = 1, N ==5 area 3,4,5,NA) Surgical scissors RR115_6 (Y = RR115A6 (Y = No Data in minor surgical "Yes", N = "No", "Yes", N = area NA) Surgical scissors RR115_6 (Y = RR115A6 (Y = No Data in minor surgical "Yes", N = "No", "Yes", N = area NA) Sutures in minor U125_09 (Y = U125_09 (Y = U125_09 in No", NA) Sutures in minor U125_09 (Y = U125_09 (Y = U125_09 in No", NA) Surgical area 1,2; N = 3,4,5) 1; N = 2,3,4,5) ==5		Oxygen	HH10122 (Y =	HH101A22 (YNo Data	1,2,3,4
concentrator) HH101_23 HH101A23 (Y (cylinder) (Y == "Yes", N = "Yes", N = "No", "No", NA) Retractor in RR115_5 (Y =RR115A5 (Y = No Data			"Yes", N = "No",	= "Yes", N =	
(cylinder) (Y == "Yes", N = "Yes", N = "No", "No", NA) Retractor in RR115_5 (Y =RR115A5 (Y =No Data		(cylinder or	NA) OR	"No", NA) OR	
"Yes", N = "No", "No", NA) Retractor in RR115_5 (Y = RR115A5 (Y = No Data minor surgical "Yes", N = "No", "Yes", N = NA)) Scalpel in minor RR115_4 (Y = RR115A4 (Y = No Data surgical area "Yes", N = "No", "Yes", N = NA)) Skin disinfectant U125_05 (Y = U125_05 (Y		concentrator)	НН10123	HH101A23 (Y	
Retractor in RR115_5 (Y = RR115A5 (Y = No Data			(cylinder) (Y =	= "Yes", N =	
Retractor in RR115_5 (Y = RR115A5 (Y = No Data minor surgical "Yes", N = "No", "Yes", N = "No", NA)) Scalpel in minor RR115_4 (Y = RR115A4 (Y = No Data surgical area "Yes", N = "No", "Yes", N = "No", NA)) Skin disinfectant U125_05 (Y = U125_05 (Y = U125_05 1,2,3,4 in minor surgical 1,2; N = 1, N ==5 area 3,4,5,NA) Surgical scissors RR115_6 (Y = RR115A6 (Y = No Data 1,2,3 in minor surgical "Yes", N = "No", "Yes", N = area NA) Sutures in minor U125_09 (Y = U125_09 (Y = U125_09 1,2,3,4 surgical area 1,2; N = 3,4,5) 1; N = 2,3,4,5) ==5			"Yes", N = "No",	"No", NA)	
minor surgical "Yes", N = "No", "Yes", N = "No", NA)) Scalpel in minor RR115_4 (Y = RR115A4 (Y = No Data surgical area "Yes", N = "No", Yes", N = "No", NA)) Skin disinfectant U125_05 (Y = U125_05 (Y = U125_05 1,2,3,4 in minor surgical 1,2; N = 1, N ==5 area 3,4,5,NA) Surgical scissors RR115_6 (Y = RR115A6 (Y = No Data 1,2,3 in minor surgical "Yes", N = "No", "Yes", N = area NA) Sutures in minor U125_09 (Y = U125_09 (Y = U125_09 1,2,3,4 surgical area 1,2; N = 3,4,5) 1; N = 2,3,4,5) ==5			NA)		
area NA)) "No", NA)) Scalpel in minor RR115_4 (Y = RR115A4 (Y = No Data 1,2,3 surgical area "Yes", N = "No", "Yes", N = NA)) "No", NA)) Skin disinfectant U125_05 (Y = U125_05 (Y = U125_05 1,2,3,4 in minor surgical 1,2; N = 1, N ===5 area 3,4,5,NA) 2,3,4,5,NA) Surgical scissors RR115_6 (Y = RR115A6 (Y = No Data 1,2,3 in minor surgical "Yes", N = "No", "Yes", N = area NA) "No", NA) Sutures in minor U125_09 (Y = U125_09 (Y = U125_09 1,2,3,4 surgical area 1,2; N = 3,4,5) 1; N = 2,3,4,5) ==5		Retractor in	$RR115_5 (Y =$	RR115A5 (Y = No Data	1,2,3
Scalpel in minor RR115_4 (Y = RR115A4 (Y = No Data surgical area "Yes", N = "No", "Yes", N = "No", NA)) Skin disinfectant U125_05 (Y = U125_05 (Y = U125_05 1,2,3,4 in minor surgical 1,2; N = 1, N ===5 area 3,4,5,NA) Surgical scissors RR115_6 (Y = RR115A6 (Y = No Data in minor surgical "Yes", N = "No", "Yes", N = area NA) Sutures in minor U125_09 (Y = U125_09 (Y = U125_09 1,2,3,4 surgical area 1,2; N = 3,4,5) 1; N = 2,3,4,5) ==5		minor surgical	"Yes", N = "No",	"Yes", N =	
surgical area "Yes", N = "No", "Yes", N = NA)) Skin disinfectantU125_05 (Y = U125_05 (Y = U125_05 1,2,3,4)) in minor surgical 1,2; N = 1, N ===5 area 3,4,5,NA) 2,3,4,5,NA) Surgical scissorsRR115_6 (Y = RR115A6 (Y = No Data 1,2,3)) in minor surgical "Yes", N = "No", "Yes", N = area NA) Sutures in minorU125_09 (Y = U125_09 (Y = U125_09 1,2,3,4)) surgical area 1,2; N = 3,4,5) 1; N = 2,3,4,5) ==5		area	NA))	"No", NA))	
NA)) Skin disinfectantU125_05 (Y = U125_05 (Y = U125_05 1,2,3,4 in minor surgical 1,2; N = 1, N ===5 area 3,4,5,NA) Surgical scissors RR115_6 (Y = RR115A6 (Y = No Data in minor surgical "Yes", N = "No", "Yes", N = area NA) Sutures in minorU125_09 (Y = U125_09 (Y = U125_09 1,2,3,4 surgical area 1,2; N = 3,4,5) 1; N = 2,3,4,5) ==5		Scalpel in minor	$RR115_4 (Y =$	RR115A4 (Y = No Data	1,2,3
Skin disinfectant U125_05 (Y = U125_05 (Y = U125_05 1,2,3,4 in minor surgical 1,2; N = 1, N ===5 area 3,4,5,NA) 2,3,4,5,NA) Surgical scissors RR115_6 (Y = RR115A6 (Y = No Data in minor surgical "Yes", N = "No", "Yes", N = area NA) "No", NA) Sutures in minor U125_09 (Y = U125_09 (Y = U125_09 1,2,3,4 surgical area 1,2; N = 3,4,5) 1; N = 2,3,4,5) ==5		surgical area	"Yes", N = "No",	"Yes", N =	
in minor surgical 1,2; N = 1, N ===5 area 3,4,5,NA) 2,3,4,5,NA) Surgical scissors RR115_6 (Y = RR115A6 (Y = No Data in minor surgical "Yes", N = "No", "Yes", N = area NA) "No", NA) Sutures in minor U125_09 (Y = U125_09 (Y = U125_09 1,2,3,4 surgical area 1,2; N = 3,4,5) 1; N = 2,3,4,5) ==5			NA))	"No", NA))	
area 3,4,5,NA) 2,3,4,5,NA) Surgical scissors RR115_6 (Y = RR115A6 (Y = No Data 1,2,3 in minor surgical "Yes", N = "No", "Yes", N = area NA) "No", NA) Sutures in minor U125_09 (Y = U125_09 (Y = U125_09 1,2,3,4 surgical area 1,2; N = 3,4,5) 1; N = 2,3,4,5) ==5		Skin disinfectant	$U125_05 (Y =$	$U125_05 (Y = U125_05)$	1,2,3,4
Surgical scissors RR115_6 (Y = RR115A6 (Y = No Data in minor surgical "Yes", N = "No", "Yes", N = area NA) "No", NA) Sutures in minor U125_09 (Y = U125_09 (Y = U125_09 I),2,3,4 surgical area 1,2; N = 3,4,5) 1; N = 2,3,4,5) ==5		in minor surgical	1,2; N =	1, N ===5	
in minor surgical "Yes", N = "No", "Yes", N = area NA) "No", NA) Sutures in minor U125_09 (Y = U125_09 (Y = U125_09 1,2,3,4 surgical area 1,2; N = 3,4,5) 1; N = 2,3,4,5) ==5		area	3,4,5,NA)	2,3,4,5,NA)	
in minor surgical "Yes", N = "No", "Yes", N = area NA) "No", NA) Sutures in minor U125_09 (Y = U125_09 (Y = U125_09 1,2,3,4 surgical area 1,2; N = 3,4,5) 1; N = 2,3,4,5) ==5					1,2,3
Sutures in minor U125_09 (Y = U125_09 (Y = U125_09 1,2,3,4 surgical area 1,2; N = 3,4,5) 1; N = 2,3,4,5) ==5		in minor surgical	"Yes", N = "No",	"Yes", N =	
surgical area $1,2; N = 3,4,5)$ $1; N = 2,3,4,5) = -5$		area	NA)	"No", NA)	
		Sutures in minor	$U125_09 (Y =$	$U125_09 (Y = U125_09)$	1,2,3,4
T : A PRINT O OF PRINTS OF P. P.		surgical area	1,2; N = 3,4,5)	1; N = 2,3,4,5) ==5	
Tourniquet in RR115_8 (Y = RR115A8 (Y = No Data 1,2,3		Tourniquet in	$RR115_8 (Y =$	RR115A8 (Y = No Data	1,2,3
minor surgical "Yes", N = "No", "Yes", N =		minor surgical	"Yes", N = "No",	"Yes", N =	
area NA) "No", NA)		area	NA)	"No", NA)	

Part 2: Chronic Conditions

Conditions	Availability of	Availability	Functionality	"Never	Facility
	complete	Indicators	Indicators	Available"	Types
	essential			Data	Surveyed
	equipment and			Availability	
	medications				
Chronic asthma	Beclomethasone	$U103_09 (Y =$	U103_09 (Y =	U103_09	1,2,3,4

	inhaler	1,2; N =	1; N =	==5	
		3,4,5,NA			
		$U103 \ 21 \ (Y =$		U103 21	1,2,3,4
	inhaler	1,2; N =	_ `	_	1,2,5,1
		3,4,5,NA)		· ·	
		HH101 13 (Y	-	No Data	1,2,3,4
		= "Yes", N =	,		1,2,5,1
		"No", NA)			
Hypertension (stage 1	At least two of:	-		U103 04	1,2,3,4
, ,	calcium channel		U103 05,	_	-,-,-, :
*			U103 06,		
		_	U103 07	_	
		(Y = 1,2; N =	_		
		,		==5 AND	
			,	U103 07	
				==5	
	Blood pressure	HH101 15 (Y	HH101A15	No data	1,2,3,4
	apparatus	= "Yes, N =	(Y = "Yes", N		
		"No",NA)	= "No",NA)		
	Stethoscope	HH101 13 (Y	HH101A3 (Y	No data	1,2,3,4
	_	= "Yes", N =	= "Yes", N =		
		"No", NA)	"No", NA)		
Hypertension requiring	At least three of:	U103_04,	U103_04,	U103_04	1,2,3,4
three or	calcium channel	U103_05,	U103_05,	==5 AND	
more antihypertensive	blocker, ACE	U103_06,	U103_06,	U103_05	
classes	inhibitor,thiazide,	U103_07	U103_07	==5 AND	
	atenolol	(Y = 1,2; N =	(Y = 1; N = 2,	U103_06	
		3,4,5)	3,4,5)	==5 AND	
				U103_07	
				==5	
	Blood pressure	HH10115 (Y	HH101A15	No data	1,2,3,4
	apparatus	= "Yes, N =	(Y = "Yes", N		
		"No",NA)	= "No",NA)		
	Stethoscope	HH101_13 (Y	HH101A3 (Y	No data	1,2,3,4
		= "Yes", N =	= "Yes", N =		
		"No", NA)	"No", NA)		
Heart failure	Adult scale	HH101_1 (Y =	HH101A1 (Y	No Data	1,2,3,4
		"Yes", N =	= "Yes", N =		
		"No", NA)	"No", NA)		
	Atenolol or other	$U103_06 (Y =$	U103_06 (Y =	U103_06	1,2,3,4
		1,2; N =		==5	
		3,4,5,NA)	2,3,4,5,NA)		

	Blood pressure	HH101 15 (Y	HH101A15	No data	1,2,3,4
	_	= "Yes, N =			
		"No",NA)			
		U103 04 (Y =		U103_04	1,2,3,4
	enalapril or other	_ `	_ `	_	1,2,5,1
	-	3,4,5,NA)			
		$U103 \ 13 \ (Y =$	-	U103 13	1,2,3,4
	r drosennae	1,2; N =	_ `	_	1,2,5,1
		3,4,5,NA)	· ·		
			, , , , ,		
	Stethoscope	HH101 13 (Y	HH101A3 (Y	No data	1,2,3,4
	1	= "Yes", N =	· ·		, ,- ,
		"No", NA)	"No", NA)		
	Ultrasound	T125 02 (Y =		No Data	1,2,3
	equipment	1,2,3; N =	1; N =		
		4,NA)	2,3,4,NA)		
chronic RHD	Benzathine	$U106_{18} (Y =$	U106_18 (Y =	U106_18	1,2,3,4
	penicillin	1,2; N =	1; N =	==5	
		3,4,5,NA)	2,3,4,5,NA)		
	Injectable	$U125_20 (Y =$	U125_20 (Y =	U125_20	1,2,3
	epinephrine	1,2; N =	1; N =	==5 AND	
		3,4,5,NA) OR	2,3,4,5,NA)	U103_12	
		$U103_{12} (Y =$	OR U103_12	==5	
		1,2; N =	(Y = 1; N =		
		3,4,5,NA)			
Type 1 diabetes	Blood glucose			No data	1,2,3,4
	test equipment				
	Insulin	$U103_02 (Y =$		_	1,2,3,4
		1,2; N =			
		3,4,5,NA)	2,3,4,5,NA)		
Type 2 diabetes		$T105_01 (Y =$		No data	1,2,3,4
	test equipment	1,2; N = 3,NA)			
		$U103_01 (Y =$			1,2,3,4
	glibenclamide	1,2; N =			
		3,4,5,NA) OR			
		$U103_14 (Y =$	_	_	
		1,2; N =	`	==5	
		3,4,5,NA)			
Pain care	_	$U127_07 (Y = $		_	1,2,3
	-	1,2; N		==5	
	pethidine	=3,4,5,NA)	2,3,4,5,NA)		

Oral 1	pain U103_20	OR U103_	20 OR U103	_20	1,2,3,4
medication	U103_17	OR U103_	17 OR ==5	AND	
(paracetamol,	U111_08	OR U111_	08 OR U103	_17	
ibuprofen, asp	oirin U103_08;	U103_	08; ==5	AND	
or diclofenac)	Y = 1,2;	N = Y =	1; N = U111	_08	
	3,4,5,NA	2,3,4,5	5,NA ==5	AND	
			U103	_08	
			==5		

^{*} Facility types: 1 = central hospitals, 2 = district hospitals, 3 = rural/community hospitals, 4 = health centres

BMJ Open Page 28 of 38

Appendix Table 4: Missingness in HHFA data

			Appendix 1a	able 4: Missingn	ess in HHFA a	ata			
		Health Center (n=471)		Rural Co Hospital	•	District Hospital (n=48)		Central Hospital (n=4)	
			Missing	g data					
Condition	Essential Equipment & Medication	Available Components	Functional Components	Available Components	Functional Components	Available Components	Functional Components	Available Components	Functional Components
Chronic Condition	ons	4							
Chronic asthma	Beclomethasone inhaler	0%	0%	0%	0%	0%	0%	0%	0%
	Salbutamol inhaler	0%	0%	0%	0%	0%	0%	0%	0%
	Stethoscope	1%	1%	0%	0%	0%	0%	0%	0%
	At least two of: calcium channel blocker, ACE inhibitor, thiazide,	00/	00/	00/	00/		00/	00/	00/
	atenolol	0%	0%	0%	0%	0%	0%	0%	0%
Hypertension	Blood pressure apparatus	1%	7%	0%	0%	0%	0%	0%	0%
(stage 1 or 2)	Stethoscope	1%	1%	0%	0%	0%	0%	0%	0%
Type 1 diabetes	Blood glucose	2%	100%	0%	100%	0%	100%	0%	100%

	test equipment								
	Insulin	0%	0%	0%	0%	0%	0%	0%	0%
	Blood glucose								
	test equipment	2%	100%	0%	100%	0%	100%	0%	100%
	Metformin or								
Type 2 diabetes	glibenclamide	0%	0%	0%	0%	0%	0%	0%	0%
	Oral pain			0%	0%	0%	0%	0%	0%
	medication	0%	0%	U70	070	0%	0%	070	070
	Injectable								
	morphine or			15%	15%	17%	17%	0%	0%
Pain care	pethidine	99%	99%						
	At least three of:			10.					
	calcium channel				· ·				
	blocker, ACE				10.				
Hypertension	inhibitor,thiazide,				C/1				
requiring three	atenolol	0%	0%	0%	0%	0%	0%	0%	0%
or more	Blood pressure					04			
antihypertensive	apparatus	1%	7%	0%	0%	0%	0%	0%	0%
classes	Stethoscope	1%	1%	0%	0%	0%	0%	0%	0%
	Adult scale	1%	7%	0%	2%	0%	2%	0%	0%
	Atenolol or other								
	beta-blocker	0%	0%	0%	0%	0%	0%	0%	0%
	Blood pressure								
Heart failure	apparatus	1%	7%	0%	0%	0%	0%	0%	0%

	Captopril, enalapril or other								
	ACE inhibitor	0%	0%	0%	0%	0%	0%	0%	0%
	Furosemide	0%	0%	0%	0%	0%	0%	0%	0%
	Stethoscope	1%	1%	0%	0%	0%	0%	0%	0%
	Ultrasound equipment	99%	99%	15%	15%	17%	17%	0%	0%
	Benzathine penicillin	0%	0%	0%	0%	0%	0%	0%	0%
chronic RHD	Injectable epinephrine	0%	0%	0%	0%	0%	0%	0%	0%
Acute Condition	is								
	Functional X-ray machine	99%	99%	15%	15%	17%	17%	0%	0%
	Oxygen availability		7770		Ch		1,73	370	070
	(cylinder or concentrator)	1%	75%	0%	12%	0%	13%	0%	0%
	Peak flow meter in NCD or general								
	outpatient area	100%	100%	100%	100%	100%	100%	100%	100%
Mild/moderate acute Asthma	Prednisolone	0%	0%	0%	0%	0%	0%	0%	0%
acute / Islimia	Pulse oximeter	2%	84%	2%	8%	2%	8%	0%	0%

	Salbutamol								
	inhaler	0%	0%	0%	0%	0%	0%	0%	0%
	Functional X-ray								
	machine	99%	99%	15%	15%	17%	17%	0%	0%
	Oxygen								
	availability								
	(cylinder or								
	concentrator)	1%	75%	0%	12%	0%	13%	0%	0%
	Peak flow meter								
	in NCD or								
	general		-0						
	outpatient area	100%	100%	100%	100%	100%	100%	100%	100%
	Prednisolone	0%	0%	0%	0%	0%	0%	0%	0%
	Pulse oximeter	2%	84%	2%	8%	2%	8%	0%	0%
	Salbutamol								
	inhaler	0%	0%	0%	0%	0%	0%	0%	0%
	Micro nebulizer					O_{Δ}			
	in NCD or					_///			
	general								
	outpatient area	100%	100%	100%	100%	100%	100%	100%	100%
Moderate/severe	Hydrocortisone								
acute Asthma	injection	0%	0%	0%	0%	0%	0%	0%	0%
	Blood glucose								
Acute diabetes	test equipment	2%	100%	0%	100%	0%	100%	0%	100%

	Blood pressure								
	apparatus in								
	NCD or general								
	outpatient area	1%	7%	0%	0%	0%	0%	0%	0%
	Infusion kit for								
	intravenous								
	fluids	11%	100%	6%	100%	6%	100%	0%	100%
	Injectable								
	glucose	0%	0%	0%	0%	0%	0%	0%	0%
	Insulin	0%	0%	0%	0%	0%	0%	0%	0%
	Liver and kidney								
	function								
	diagnostics								
	(creatinine,				/_				
	electrolytes)	97%	97%	6%	6%	6%	6%	0%	0%
	Diazepam								
Acute epilepsy	injection	99%	99%	15%	15%	17%	17%	0%	0%
	Lidocaine in								
	minor surgical								
	area	0%	0%	0%	0%	0%	0%	0%	0%
	Nasogastric								
	tubes in minor								
Injuries/ acute	surgical area	99%	99%	13%	23%	15%	25%	0%	0%
minor surgical	Needle holder in								
conditions+	minor surgical	99%	99%	13%	15%	15%	17%	0%	0%

area								
Oxygen								
availability								
(cylinder or								
concentrator)	1%	75%	0%	12%	0%	13%	0%	0%
Retractor in								
minor surgical								
area	99%	99%	13%	15%	15%	17%	0%	0%
Scalpel in minor		0						
surgical area	99%	99%	13%	15%	15%	17%	0%	0%
Skin disinfectan	t		<i>/</i> ~					
in minor surgica	1							
area	0%	0%	0%	0%	0%	0%	0%	0%
Surgical scissors	3			1				
in minor surgica	1			(0)				
area	99%	99%	13%	15%	15%	17%	0%	0%
Sutures in minor	:							
surgical area	0%	0%	0%	0%	0%	0%	0%	0%
Tourniquet in								
minor surgical								
area	99%	99%	13%	31%	15%	31%	0%	259

Appendix Table 5: nebulizer and peak-flow meter availability from SPA data, 2015

Medical	Facility type	Total	Facilities	%
component		facilities	with	availability
			availability	
Nebulizer	Central hospital	4	3	75.00
	District hospital	24	6	25.00
	Other hospital	47	28	59.25
	Rural / community	41	9	21.95
	hospital			
	Health center	473	24	5.07
	Clinic	317	38	12.02
	Health post	20	NA	NA
	Maternity	4	NA	NA
	Dispensary	47	1	2.00
	Total	977	109	11.09
Peak-flow	Central hospital	4	1	25.00
meter				
	District hospital	24	1	4.17
	Other hospital	47	13	27.58
	Rural / community	41	2	4.88
	hospital			
	Health center	473	8	1.68
	Clinic	317	12	3.79
	Health post	20	NA	0.00
	Maternity	4	NA	0.00
	Dispensary	47	NA	0.00
	Total	977	37	3.76

Appendix Figure 1: Service readiness and availability of equipment and Medicines by level

Part-1

		Essential Equipment				
Category	Condition	& Medicines	I	PHC (% functional)	9	STC (% functional)
		SR	8	8%	40	40%
	Chronic	Beclomethasone inhaler	8	8%	42	42%
	Asthma	Salbutamol inhaler	71	71%	88	88%
		Stethoscope	93	93%	100	100%
		SR	34	34%	88	88%
	HTN (Stage 1	>=2: CCB, ACEI, thiazide, atenolol	37	37%	88	88%
	or 2)	Blood pressure apparatus	89	89%	98	98%
		Stethoscope	93	93%	100	100%
	True 1	SR	5	5%	88	88%
	Type 1 diabetes	Blood glucose apparatus	43	43%	98	98%
	diabetes	Insulin	6	6%	90	90%
		SR	21	21%	94	94%
	Type 2	Blood glucose apparatus	43	43%	98	98%
	diabetes	Metformin/glibenclamide	30	30%	96	96%
	Chronic pain	SR	95	95%	100	100%
	(oral)	Oral pain medicine	95	95%	100	100%
	Chronic pain	SR	22	22%	29	29%
Chronic Conditions	(Injectable care)*	Injectable morphine/pethidine	22	22%	29	29%
		SR	15	15%	75	75%
	HTN	>=3: CCB, ACEI, thiazide, atenolol	16	16%	75	75%
	(complicated)	Blood pressure apparatus	89	89%	98	98%
		Stethoscope	93	93%	100	100%
		SR	22	22%	38	38%
		Adult scale	95	95%	98	98%
		Atenolol or other beta- blocker	71	71%	79	79%
	Chronic Heart Failure*	Blood pressure apparatus	93	93%	98	98%
	Turidie	Captopril, enalapril or other ACEI	66	66%	75	75%
		FRS	71	71%	85	<mark>8</mark> 5%
		Stethoscope	95	95%	100	100%
		Ultrasound equipment	34	34%	77	77%
		SR	32	32%	44	44%
	Chronic RHD*	BPG	78	78%	83	83%
		Injectable epinephrine	32	32%	56	56%

Part -2

		Essential Equipment					-
Category	Condition	& Medicines	PHC (% functional)			STC (% functional)	
		SR	17		17%	48	48%
		Oxygen availability	85		85 %	88	88%
	Acute Asthma	Peak flow meter	NA	NA		NA	NA
	(Mild/	Prednisolone	73		73%	88	88%
	moderate)*	Pulse oximeter	59		59%	88	88%
		Salbutamol inhaler	93		93%	88	88%
		X-ray	29		29%	73	73%
		SR	15		15%	42	42%
		X-ray	29		29%	73	73%
		Oxygen availability	85		85%	88	88%
	Acute	Peak flow meter	NA	NA		NA	NA
	Asthma (Moderate/	Prednisolone	73		73%	88	88%
	severe)*	Pulse oximeter	60		60%	88	88%
	severe)**	Salbutamol inhaler	93		93%	88	88%
		Micro nebuliser	NA	NA		NA	NA
		Hydrocortisone injection	61		61%	85	8 5%
Acute Conditions	Acute	SR	12		12%	87	87%
		Blood glucose apparatus	95		95%	98	98%
		Blood pressure apparatu	93		93%	98	98%
	diabetic	IV infusion kit	90		90%	92	92%
	event*	Injectable glucose	80		<mark>8</mark> 0%	92	92%
		Insulin	46		46%	90	90%
		Liver and kidney diagno	17		17%	31	31%
	Acute	SR	36		36%	85	85%
	epilepsy*	Diazepam injection	37		37%	85	8 5%
		SR	24		24%	46	46%
		Lidocaine	95		95%	98	98%
		Nasogastric tubes	66		66%	77	77%
		Needle holder	90		90%	85	85%
	Injuries/acute	Oxygen availability	85		85%	88	88%
	minor surgical	' '	51		51%	85	85%
	conditions*	Scalpel	85		85%	85	85%
		Skin disinfectant	85		85%	87	87%
		Surgical scissors	78		78%	85	85%
		Sutures	90		90%	98	98%
		Tourniquet	59		59%	69	69%

STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies

	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the	V
		abstract	
		(b) Provide in the abstract an informative and balanced summary of what	$\sqrt{}$
		was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being	$\sqrt{}$
Objectives	3	reported State specific objectives, including any prespecified hypotheses	√
Methods			
Study design	4	Present key elements of study design early in the paper	√
Setting	5	Describe the setting, locations, and relevant dates, including periods of	
Setting		recruitment, exposure, follow-up, and data collection	,
1		(a) Give the eligibility criteria, and the sources and methods of selection of participants	$\sqrt{}$
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders,	√
Variables	,	and effect modifiers. Give diagnostic criteria, if applicable	,
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	
measurement		assessment (measurement). Describe comparability of assessment methods	
		if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	√
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	V
		applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	$\sqrt{}$
		-	ما
		(b) Describe any methods used to examine subgroups and interactions	√
		(c) Explain how missing data were addressed	ν
		(d) If applicable, describe analytical methods taking account of sampling	NA
		strategy (a) Describe any consitivity analyses	NT A
Results		(e) Describe any sensitivity analyses	NA
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers	NA
i articipants	13	potentially eligible, examined for eligibility, confirmed eligible, included in	11/1
		the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA NA
Descriptive data	1.4*		
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	NA
		(b) Indicate number of participants with missing data for each variable of	√
		interest	V
Outcome data	15*	Report numbers of outcome events or summary measures	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	NA
		estimates and their precision (eg, 95% confidence interval). Make clear	- 12 1
		which confounders were adjusted for and why they were included	
		John John Sandon word and not and with they were mended	

		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute	NA
		risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and	V
-		sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	$\sqrt{}$
Limitations	19	Discuss limitations of the study, taking into account sources of potential	$\sqrt{}$
		bias or imprecision. Discuss both direction and magnitude of any potential	
		bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	$\sqrt{}$
		limitations, multiplicity of analyses, results from similar studies, and other	
		relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	√
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study	
		and, if applicable, for the original study on which the present article is based	

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.